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Abstract
Wasted (wst) is a recessive spontaneous mutation in the mouse resulting in a complex
phenotype incorporating neuromuscular wasting and atrophy of the organs of the
immune system. Lymphoid derived cells also display an aberrant response to ionising
radiation. The genetic lesion in wasted mice is a 15.8Kb deletion on mouse chromosome
2. This deletion removes the promoter and first non-coding exon of eukaryotic
elongation factor la2 or eEFlA2. This is a tissue specific isoform of eEFl A1 found in
the terminally differentiated cells of the brain, heart and muscle, thus providing a
feasible hypothesis for the neuromuscular phenotype. However, how an essential
eEFlA2 knockout causes an immunological phenotype remains unclear.
Here I will describe the study of a novel gene in close proximity to the wasted deletion.
This new gene Clwd (C/ose to the Wasted Deletion) is a small 1.2kb gene which appears
(from EST data) to be ubiquitously expressed. It has several alternative splice forms and
a short conserved upstream Open Reading Frame or uORF. The protein it encodes is
115 amino acids long with no striking homology to other proteins in the database. These
features have been confirmed using RT-PCR and by generating and using an anti-
peptide antibody to Clwd. Immunocytochemistry shows Clwd to be associated with the
nuclear membrane. Upon the application ofRNA interference (RNAi) to silence the
Clwd gene transiently in mammalian cell culture, cells lacking Clwd display
dysregulation of the cell cycle with cells appearing to have disrupted nuclei and slowed
growth.
As a result of this study I believe it unlikely that Clwd is responsible for the
immunological phenotype ofwasted mice. There is no difference in Clwd mRNA or
protein expression between wasted and wild type controls. A transgenic project has been
carried out in the lab whereby mice were injected with a BAC containing the whole
genomic region surrounding the deletion, and a BAC containing the whole genomic
region, but with eEFlA2 knocked out. Analysis of these animals suggests the pathology
xii
ofwasted is due solely to the lack of eEFlA2.1 will describe some preliminary studies
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INTRODUCTION
Chapter 1 Introduction 1
1. Introduction
1.1 Introduction
The aim of this thesis was to determine if a newly discovered gene contributed to the
pathology of the mouse mutant wasted. In order to introduce this work, therefore I
will first discuss the pathology of the wasted mouse before going on to address the
nature of the genetic lesion responsible for this pathology. Finally I will discuss the
reasons why I chose to examine an additional novel gene to assess its contribution, if
any, to the phenotype of this mutant.
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1.2 Pathology of the wasted mouse
In 1972 an autosomal recessive spontaneous mutation wst (wasted) arose in the
inbred HRS/J colony maintained in the Mouse Mutant Stocks Centre at The Jackson
Laboratory1. Mice homozygous for this mutation appeared normal directly after birth
but at 21 days of age began to develop signs of neuromuscular degeneration i.e.
wasting ofmuscles, tremor and uncoordinated body movements. The affected mice
did not live beyond 30 days. In addition they also displayed sudden progressive
hypoplasia of the spleen, thymus and lymph nodes, again beginning the third week of
life. The spleen and thymus begin to atrophy and, by the time of death, the thymus in
particular has almost disappeared. (C.M. Abbott personal communication)
1.2.1 Neuromuscular degeneration
Examining the neurological aspects of the wasted pathology in more detail, it was
found that these mice displayed weight loss, tremors, incoordination and a decreased
interest in their surrounding environment from post-natal day 21 (P21). Hind-limb
paralysis followed, and by 28 to 31 days these mice were dead. The tremor observed
involved all four limbs and was of high frequency but low amplitude. On a cellular
level, these mice suffered from extensive vacuolar degeneration of the anterior horn
cells of the spinal cord with less severe abnormalities in the motor nuclei of the
brainstem including an abnormal accumulation of phosphorylated neurofilament
heavy subunit (NF-H) in the perikarya ofmotor neurons2.
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1.2.2 Immune system abnormalities
In 1982 Shultz et al[ described the marked lymphoid hypoplasia with significantly
decreased spleen, thymus and lymph node to body weight ratios by 28 days of age
that is characteristic of the wst/wst mouse. It was also noted that this hypoplasia was
not restricted to a single major lymphocyte sub-population, and that wst/wst mice
exhibited an impairment of delayed-type hypersensitivity (DTH) response to sheep
red blood cells - i.e. significantly decreased DTH responses 4 days after priming
compared to heterozygous controls. In addition, the authors noted a four-fold greater
incidence of chromosome damage (breaks, gaps and fragments of chromosomes) in
the bone marrow ofwst/wst mice than in control littermates. When y irradiated, 80%
ofmetaphase wst/wst cells exhibited chromosomal damage compared to 30% of
controls.
This paper proposed that mice homozygous for the wst mutation could be an animal
model of ataxia telangiectasia (AT). This is an autosomal recessive disorder
characterised by cerebellar ataxia, telangiectases, immune defects, and predisposition
to malignancy. Chromosomal breakage is also a feature. AT cells are abnormally
sensitive to killing by ionising radiation and abnormally resistant to inhibition of
DNA synthesis by ionising radiation. Thus the initial hope that wasted mouse would
be a good model for AT was a logical one.
However, this was found not to be the case, initially as result ofmapping studies
linking AT to chromosome 1 lqJ (the wst mutation had been mapped to chromosome
24 in a region exhibiting conservation of synteny with human chromosome 20). This
was then confirmed by the discovery of the ATM (Ataxia Telangiectasia Mutated)
gene5 and the wasted deletion6.
Nevertheless, it was this hypothesis that biased much of the early research into the
wst mutation. This meant that much of the discussion of the results found in these
papers were concerned with whether or not the various observations made were
similar to the AT phenotype - making for a large amount ofpublished negative
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results; e.g. The only result published in a paper by Nordeen et al in 19847 was that
neither y irradiation nor bleomycin-resistant component ofDNA replication
characteristic ofAT fibroblasts was observed in cell lines from wst/wst mice. But not
all previous work was so narrow in its viewpoint.
In 1986 Tezuka et als noted the age-dependent increase in the frequency of
spontaneous chromosome abnormalities in bone-marrow cells, and that in the wst
lymphoid system the frequency of chromosome aberrations induced by y irradiation
reaches 13-fold that of normal mice by day 26. An absence of y ray-induced mitotic
delay was not apparent in wst/wst bone marrow, yet when the primer-activating
enzyme activity was examined (a function of cellular DNA repair), there was no
decrease in activity at 24 days. This suggested that the chromosomal aberrations seen
were not as a result of dysregulation of the DNA repair function of the affected cells.
In addition, the fact that y rays could not induce a mitotic delay begins to point
toward a potential deficit in the cell cycle checkpoint. This suggested that rather than
being unable to repair damaged DNA, the wst/wst cells could not sense the damage
that was occurring to their DNA and so continued to replicate and proliferate,
resulting in an unusually large number of cells with chromosome abnormalities.
This conclusion was reinforced by work done by Inoue et a? in 1986 as this group
looked at the levels ofDNA synthesis following treatment ofwst/wst spleen with
bleomycin, 4NQO (4-nitroquinoline 1-oxide), y irradiation and UV irradiation. It was
discovered that following treatment with bleomycin, while control spleen cells' DNA
synthesis decreased by 80%, that ofwst/wst spleen cells decreased by only 30%.
Similar results were found for 4NQO, and there was also a significant difference
between controls and wasted mice for y irradiation, but not as large a difference. UV
radiation did not result in a difference between control and wst/wst. Bleomycin is a
radiomimetic which exerts its effect by a sequence-specific degradation ofDNA10.
4NQO (a UV mimetic) binds to DNA and produces adducts resulting in base
substitution11. This is unusual as although 4NQO is primarily used as a UV mimetic,
UV radiation itself did not distinguish wst/wst cells from wild type cells. However
this could be because 4NQO does not produce a unique lesion as UV does but rather
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multiple forms ofDNA damage some ofwhich could resemble y irradiation. The
DNA defects caused by bleomycin, 4NQO and y irradiation should be devastating
insults to the cell, and induce apoptosis/cell cycle arrest. This is not the case in
wst/wst lymphoid cells, and so again we have evidence of the uncoupling of the DNA
damage-sensing apparatus of the cell and the cell cycle checkpoint mediators.
Van Buul et al in 198712, and again in 199113, brought two new observations to light.
Firstly in 1987 that wst/wst polychromatic erythrocytes exhibited an enhanced
spontaneous rate ofmicronuclei formation - which reflects the prevalence of
chromosome breakage. Secondly, in 1991 that translocation induction in the germ
cells ofwst/wst mice irradiated at 3-4 days old and examined at 21 days was normal.
This implied two conclusions:
• The wV mutation is not a good model ofAT.
• The problems inherent in the wst/wst ability to sense DNA damage
exemplified by the lymphoid chromosomal aberrations, was not a universal
phenomenon.
This last point is highly significant and is reinforced by the previous work showing
that the abnormal response to radiation was not seen in wst/wst fibroblasts either7.
Indeed, it suggested that the component of a checkpoint pathway affected by the wst
mutation was a tissue-specific one.
A 1996 paper by Libertin et al14 began to make interesting observations ofwst/wst
mice without reference to AT. One such observation included an increase in the
mRNA expression from 116 (Interleukin 6), III (Interleukin 1 complex), Crp (C-
reactive protein, petaxin related), Jun (Jun oncogene), and Pdcd2, (Programmed cell
death 2) in wst/wst liver as compared to controls. It is worth noting that PDCD2, IL6
and JUN are involved in the induction of transcription associated with the onset of
apoptosis. This group had previously documented decreased expression of
interleukin 5 (thymus and spleen) and interleukin 2 receptor (thymus only) with
increased expression of interleukin 2, y interferon and transforming growth factor,
beta 1R
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When trying to interpret data of this nature, it is imperative to bear in mind the
distinction between primary and secondary phenotypes. While there may indeed be
various increases and decreases in expression of these cytokines in the liver, the
animals are undergoing severe muscle wasting and neurological abnormalities at this
stage. Therefore it is possible that these fluctuations in cytokine expression are
simply reflecting the fact that these mice are stressed and/or are not feeding as
normal rather than highlighting a specific cytokine pathway deficiency.
A more directed approach was taken by Woloschak et al16 in studying the regulation
of thymus PCNA (proliferating cell nuclear antigen) expression in wasted mice. This
study was initiated following a 2D gel electrophoresis experiment where one protein
in particular could be seen to be markedly decreased in wst/wst thymus in
comparison to wild type and heterozygous controls. (In fact in total the authors claim
that eight proteins were expressed at greater levels, and twenty-three at decreased
levels in wst/wst mice relative to controls, but only one particular protein was studied
further)
Following sequence analysis and inter-species comparisons, it was subsequently
discovered that this protein was in fact the mouse homologue ofPCNA (Proliferating
Cell Nuclear Antigen). It was also noted that this decrease was not repeated in brain
tissue. PCNA is a processivity factor for DNA polymerase 8 with its expression
associated with cell cycle progression. Given this and the fact that wst/wst lymphoid
cells exhibit a high spontaneous rate of apoptosis (meaning the cells are not
progressing through the cell cycle), some aspects of the wst/wst cell cycle were
examined. It was found that while thymocytes responded similarly to controls with
regard to concanavalin A activation, stimulation of some lymphoid cell sub-
populations with mitogens, particularly in the spleen, caused an alteration in the
fraction of cells in G2 and S phase of the cell cycle.
Potter et al17 in 1998 noted an increased level of induced and spontaneous apoptosis
in thymocytes in vivo and in vitro while the brain, lung and gut showed no such
increase. These results have been confirmed and expanded in our lab, with increased
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apoptosis seen in splenocytes also (A.H. Wyllie and C.M. Abbott, personal
communication).
While much of the previous research done into the immune system pathology of the
wasted mouse points toward a deficiency in the maintenance of the correct cell cycle
checkpoints, the nature of the cell cycle disturbance seen in this aspect of the wasted
mouse phenotype remains unclear. In addition how this phenotype is connected to
the neuromuscular deficiencies observed is also unknown.
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1.3 The wst/wst genotype and Eef1a2
In 1998, using a positional cloning/positional candidate strategy, our research group
discovered the genetic lesion responsible for the wst mutation6 Wasted mice exhibit
a 15.8kb deletion on distal chromosome 2 that removes the promoter region and first
non-coding exon of the mouse Eefla2 gene, abolishing transcription of this gene.
1.3.1 Eef1a2.
1 o
Eefla2 was originally described by Ann et al as a rat cDNA clone SI which was
discovered during the search for the Statin gene. It was found that the derived amino
acid sequence of SI shared over 92% homology with the human translation
elongation factor eEFla.
Figure 1.1 Schematic diagram of eEFIA's role in translation elongation (from ref19)
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eEFla, when complexed with GTP, delivers the aminoacylated tRNA to the A-site
of the ribosome. When appropriate codon-anticodon recognition occurs, GTP is
hydrolysed and eEFla-GDP is released from the ribosome. eEFla then interacts
with eEFIB, thereby promoting the exchange of the bound GDP for GTP to
regenerate active eEFla -GTP19
However the fact that the sequences ofSI and EEFla's 5' and 3' UTRs were less
than 20% homologous implied that SI could be a separate distinct gene, regulated
independently from EEFla. This was also implied by the difference in temporal
expression ofmRNA from SI and Eefl a in the 3T3 mouse fibroblast cell line. While
SI transcripts were found to be most abundant in the GO phase of the cell cycle of
this cell line but decreasing upon entering the G1 and S phases of the cell cycle,
Eefl a transcripts showed no such changes in abundance upon progression through
the cell cycle18.
Again the separate nature ofEefla and SI was highlighted when the same group
found that SI was in fact expressed in a highly restricted manner in both mice and
rats. Using RNase protection assays and Northern blots they found that the transcript
ofmurine SI was present only in the brain, heart and muscle i.e. organs with a large
9fl
proportion of terminally differentiated cells . It soon became clear that SI was a
bona fide gene similar to Eefl a, but regulated differently and the nomenclature was
changed to reflect this with Eeflal referring to the original Eefla and Eefla2
referring to SI. In 1996 the loci of these two genes were discovered in humans with
EEF1A1 found on chromosome 6ql4 and EEF1A2 on 20ql3.321. Comparing mRNA
expression from Eeflal and Eefla2 in rabbit it was found that Eeflal expression
was not ubiquitous as previously thought, as it was not expressed in the skeletal
muscle. Meanwhile Eefla2 was found to be expressed in the skeletal muscle, heart,
• 22brain and aorta . In addition when the post-translational modifications of the two
proteins were examined upon amino acid sequencing, it was found that while some
remained the same (both of the glycerylphosphorylethanolamine modifications in
eEFl A1 were found in eEFlA2) others differed (residues found to be dimethylated
• 99
in eEFlA1 appeared to be trimethylated in eEFl A2). With regard to the
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functionality of these two proteins, however, both these proteins had
• 22
indistinguishable activity in an in vitro translation system .
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1.3.2 Eef1a2 and wasted mice
The mouse Eefla2 gene was mapped by our group in 1998 and the wasted deletion
uncovered6. Once Eefla2 was mapped close to wst i.e. the distal portion ofmouse
chromosome 2, it became clear that this gene was a good candidate. In comparing
wst/wst and wild type mice it was found that PCRs designed to amplify exons I and
II from wst/wst mice failed, while PCR products were obtained easily from wild type
mice. This indicated the genetic lesion in wasted mice might be a deletion.
Subsequently, through a process of screening an ES cell-derived BAC library,
sequencing the genomic region surrounding Eefla2 and carefully designed PCR
experiments, the boundaries of this deletion were characterised. One end of the
deletion lay 206bp upstream of exon II ofEefla2, with the other end lying within the
gag gene of an IAP element upstream from the Eefla2 gene. Upon examining this
deletion sequence there were no known or predicted genes present. It appeared
therefore that the only gene directly affected by the deletion was Eefla2 which lost
its promoter and first exon (although this exon is non-coding). To determine the
effect of this insult to Eefla2 in wst/wst mice, the expression of the mRNA was
examined and found to be completely abolished.






Figure 1.2 Diagram showing position of wasted deletion relative to Eef1a2 locus
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1.3.3 Eef1a2 and the neuromuscular phenotype of wasted mice.
1.3.3.1 Eef1a2 in skeletal muscle
When the expression pattern ofEeflal and Eefla2 were examined more closely over
time an interesting observation was made. While it had previously been reported that
• • 22 •there was no Eeflal expression in skeletal muscle in the rabbit a more in-depth
analysis found that skeletal muscle did express Eeflal in the wild type embryo, but
that this expression tailed off rapidly following birth with almost no Eeflal
expression detectable by P21. This expression profile was almost the opposite to that
ofEefla2 whose expression levels increased dramatically following birth and begin
to plateau at about PI7 or PI86. These expression patterns are illustrated in the
diagram below (figure 1.3).
It therefore appeared that, in skeletal muscle cells at least, eEFlA2 could "take over"
from eEFlA1 i.e. eEFlA1 is not essential for living cells. If wasted mice have no
Eefla2 expression it can be easily seen that by P21 these mice will have no
functional eEFlA isoform in muscle cells and so there is no de novo translation of
mRNA. It is therefore obvious that a lack of eEFlA2 could cause the muscle wasting
and failure to gain weight seen in wasted mice from P21 onward.
Figure 1.3 Diagram of developmental switching between Eefla isoforms in skeletal muscle.
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1.3.3.2. Eef1a2 in the central nervous system
Both eEFl A1 and eEFlA2 are expressed in the central nervous system and so even
with the loss of eEFlA2, there should still be a functional translation elongation
factor present to carry out translation. When the expression ofeEFl A1 and eEFl A2
was more closely examined in the central nervous system, however, it appeared that
in the brain of adult wild type mice eEFlA2 is localised in neurons while eEFlA1 is
found in non-neuronal cells. In neurons prior to P7 eEFl A1 is the major isoform but
is later replaced by eEFlA2 which by PI4 is the only isoform present . This work
was carried out largely in P20 mouse brain, but some recent evidence using specific
eEFlA isoform antibodies in the spinal cord suggest that eEFlA1 is present in the
nuclei ofmotor neurons, while eEFlA2 localises in the cytoplasm (H.J. Newbery
personal communication). This would seem to contradict the previous study23, but it
can be seen that this paper only shows individual images of a eEFlA1-stained glial
cell and a eEFlA2-stained neuron. Because these images are not double-labelled, it
is unclear whether there would be any staining of a neuronal nucleus with the
eEFlA1 specific antibody. In addition these studies were carried out at different
sites, in the brain and spinal cord, and by different methods, immunohistochemistry
and immunofluorescence. The different sensitivities of the methods used to detect
eEFl A1 and eEFlA2 staining could be affecting the expression pattern observed or,
as the pathology of the wasted mouse is seen largely in the spinal cord, it could well
be that there are different expression patterns in these two components of the central
nervous system.
What this work has shown is that while both isoforms of eEFlA are expressed in the
central nervous system it appears that on a cellular and subcellular level the
expression patterns of these isoforms diverge resulting in organelles and/or cell types
which would be without any eEFlA isoform at all in a wst/wst mouse. This can be
interpreted therefore as evidence that the loss of eEFl A2 could account for the
neuromuscular pathology seen in the wasted mice.
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In addition to its role in translation elongation, eEFlA1 has also been shown to
exhibit other functions. It interacts with the transcription factor ZFP259
(Zinc Finger Protein 259), which in turn interacts with SMN (Survival Motor
Neuron). Binding of both SMN and eEFl A1 to ZFP259 is required for their
translocation from the cytoplasm to the nucleus. It is therefore possible that all three
proteins are part of a complex. Given the similarity of eEFlA1 and eEFlA2, it is
possible that eEFl A2 also interacts with these proteins. It is worth noting that SMN
is deleted or mutated in >95% of cases in spinal muscular atrophy. This is a form of
motor neuron disease that predominantly affects young children. Features of this
disease include the loss ofmotor neurons of the anterior horn region of the spinal
cord, the brain stem and the motor cortex and atrophy of the muscle fibres. It is
possible therefore that the post-natal lack of both eEFl A1 and eEFl A2 in wasted
muscle causes the downstream pathology through this ZFP259-SMN complex.
However it is also possible that the motor neurons are severely affected by the lack
of de novo protein synthesis because of their high metabolic requirement.
Further evidence that the loss ofeEFlA2 expression could cause the neuromuscular
deficiencies seen in wasted mice include a study where it was found that eEFl A2
could interact with the M4 muscarinic acetylcholine receptor subtype. It had
previously been shown that muscarinic activation increases dendritic translation24
and although the subtype was not specified one can speculate that perhaps it is
through eEFlA2 that this is accomplished. This suggests a specific role for eEFlA2
in translation at the dendrites ofneurons.
Additional work has found that it is upon myogenic differentiation, the expression of
eEFlA2 is activated25.
These studies, in addition to elucidating how the loss of eEFlA2 expression could
cause such damage to the wasted neuromuscular system, also begin to introduce the
idea that eEFlA1 and eEFlA2 may have differing roles within the cell, and so even
when eEFl A1 is present, this is not enough in cell types that usually express both,
i.e. eEFl A2 has a role for which eEFlA1 cannot compensate. While it has been
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shown in vitro translation systems that both eEFl A1 and eEFl A2 can function as
99
translation elongation factors , there have been several studies that suggest that
eEFl A1 plays a role in other systems in addition to translation.
One of the major functions eEFlA seems to play in the cell is with relation to the
cytoskeleton. It has been found that eEFlA binds actin filaments and microtubules in
Oft
vivo and in vitro. It binds and crosslinks actin in Dictyostelium amoebae and S.
97 •
cerevisiae . There is also evidence that it can function in the bundling and severing
ofmicrotubules - although there has been some dispute as to whether eEFlA can
sever microtubules28'29. It has also been found to be an integral part of the mitotic
• • • 90
spindle organising centres in sea urchins .
Some of the more interesting studies describe how, not only does eEFlA bind actin
but also it appears to crosslink filament actin (F-actin) in particular, to form unique
91
bundles . Also when eEFlA is overexpressed in S. cerevisiae there are no effects on
the efficiency or fidelity of translation, but in vivo there is an effect on the
morphology of the cells. In particular there is an increase in the fraction of unbudded
97
cells and the cells are larger and rounder in shape .
Why a translation elongation factor would have these functions is unclear but it could
be surmised that they grew out of its original role as a translation factor. eEFlA,
99
mRNA, ribosomes and actin can be co-localised in the cell which suggests that a
function of eEFlA, in addition to translating mRNA, has become to transport and
anchor the mRNA to actin via its actin binding properties. It can be surmised from
this that elongation factors' facility for binding and bundling actin as part of its
translation role has had offshoot effects perhaps because of its abundance in the cell
(eEFlA constitutes 1-2% of total protein in normal growing cells33). For example
when Dictyostelium discoideum is stimulated by a chemical and begins to respond to
that chemical with movement, this chemotaxis involves a sudden and dramatic
• • • • 9 ft •
increase in eEFlA -actin binding . Elsewhere it has been found that in cell lines of
higher metastatic potential there is a 30% reduction in the ratio of eEFlA to F-actin
in the cytoskeleton which the authors suggest could allow for altered cytoskeletal
organisation34.
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It is clear therefore that eEFlA does more than just make protein in a cell. But what
does this information have to do with the loss ofeEFlA2 in the central nervous
system? It means that although we know that eEFlA2 can elongate polypeptide
chains as eEFl A1 does, we are still unsure as to how much if any of the additional
functions ascribed to eEFla in the literature are also applicable to eEFlA2. In many
of the studies I have discussed the work has been done in "eEFla", with the authors
unaware of the two isoforms. This can subtly change the conclusion one can draw
from the experiments conducted. An example is the study on metastatic rat mammary
adenocarcinomas. As I've discussed before, this group found that there is a 30%
reduction in the ratio ofeEFlA to F-actin in the cytoskeleton of these cell lines34.
However this work was done using an antibody that would be predicted to recognise
both eEFlA1 and eEFlA2 as it was designed against a peptide sequence that is
identical in both of these proteins. Therefore the 30% reduction seen could actually
be not only a reduction in total eEFla but a switch from eEFl A1 to eEFl A2 for
example. If these two isoforms then had different actin bundling properties or
efficiencies it could mean that it is the switch in isoforms that causes the increased
metastatic potential.
Therefore in the case of the brain and spinal cord - the loss of one isoform - despite
the presence of the other - could still have wide-ranging effects on the cell.
In particular given the myocyte differentiation study25 - it could be that one form is
required for the growing and differentiating cell (eEFlAl) while the other is needed
for the terminally differentiated cell with definitive architecture (eEFlA2). And that
these differing roles are due to their having different actin or microtubule binding
properties rather that any change in the translation elongation role of these proteins.
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1.3.4 Eef1a2 and the immune system.
A problem arises when addressing the immune system component of the wasted
pathology with relation to the loss ofEefla2 expression. Several studies using a
range ofmethods including specific Northern blots20'22 (with probes from the 3'UTR
20
ofEeflal and Eefla2 as these are less than 20% similar), RNase protection assays
and Western blots23 with specific antibodies have concluded that there is no
expression ofEefla2/eEF\A2 in mouse23, rat20'23, rabbit22 or human23 spleen. Given
that this organ is one of the major sites of the immune system pathology, it is unclear
how the loss of expression ofEefla2 in wasted mice could effect the changes seen in
the spleen.
As discussed earlier the problems seen in the immune system such as the atrophy of
the spleen and thymus, the increase in spontaneous chromosome aberrations,
abnormal responses to DNA damaging agents, changes in rate of apoptosis appear to
point toward some sort of dysregulation of the various checkpoints of the cell cycle
in this system. Could it be possible that the loss ofEefla2 expression would cause
these sorts ofproblems? There has been some evidence that eEFlA2 can play a role
in the regulation of the growth and survival of the cell.
When Eeflal is hypo- or hyper-expressed in Balb/c 3T3 cells there are subsequent
changes in the apoptosis rate. Upon induction of serum starvation antisense Eeflal
was found to protect cells to some degree from apoptosis while Eeflal over-
expression results in a faster rate of cell death35. Hydrogen peroxide can be used to
treat cultured cells in order to induce apoptosis by oxidative challenge. When this
was carried out on H9c2 (a rat heart ventricle-derived clonogenic cell line) it was
found there was a rapid increase in eEFlA protein levels which is thought to
facilitate the apoptotic response to the oxidative stress 36 It is worth noting that the
immunoblot conducted in this study was done with a "polyclonal eEFla antibody".
From the information given it is impossible to tell if this is an eEFlAl-specific
antibody or one that would pick up both eEFlA isoforms. A 2002 study looked at
the eEFlA isoforms in differentiating myocytes and found that while eEFl A2
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expression is activated during differentiation, upon serum-starvation, eEFlA2
expression declines and eEFlA1 expression is turned on again in the dying
myotubes . This suggests that not only do these isoforms have an effect upon
apoptosis but appear to have some sort of reciprocal relationship with regard to
differentiation and apoptosis.
Given therefore that it has been shown that eEFlA1 and potentially eEFlA2 could
have an effect on the growth and survival of cells it could be possible that the loss of
eEFlA2 would have an adverse effect the apoptosis rate/cell cycle of a particular
tissue. However this still does not explain how a tissue not expressing Eefla2 could
be affected by its loss.
There was only one connection between eEFlA2 and the immune system which was
revealed in an immunology paper which addressed T-cell tolerance to endogenous
proteins expressed in a tissue specific manner37. To investigate why these proteins
are not seen as non-self, the authors used eEFlA2 as a prime example of such a
protein, as although it is highly similar to eEFlA1 it is only expressed in the skeletal
muscle, heart and brain. During the course of this work, an RT-PCR experiment was
used to look at expression of Eefla2 in the immune system. It was found that Eefla2
is expressed in bone marrow derived dendritic cells - which are antigen-presenting
cells found in both the spleen and thymus.
Ablation ofEefla2 expression in dendritic cells, if true, could be seen as the proof
that Eefla2 alone is responsible for the wst/wst phenotype. It is unclear, though, how
the loss of a translation elongation factor could result in the type of chromosome
damage observed in the lymphoid tissue especially as this damage was not confined
to dendritic cells.
Dendritic cells are often called "professional" antigen presenting cells. They function
by transporting antigens from the periphery into the inner tissues where lymphocytes
reside. They do this by trapping, engulfing and digesting antigens of very diverse
origin and then presenting these antigens to those lymphocytes that can take action
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against the antigen sampled. On encountering antigens, a highly dynamic process is
triggered in the dendritic cell, which allows it to migrate and change its phenotype
and function. This process is referred to as maturation. Upon maturation, the
dendritic cell is then able to convert the antigen into an efficacious immunogen and
express the necessary cytokines and co-stimulatory molecules to galvanise the
acquired immune system in action .
These cells are vital to the maintenance of a healthy and functioning immune system
and it is possible to see that their malfunctioning through the loss of expression of a
gene like Eefla2 would be devastating to this system. From what we know of
eEFl A2 one could predict two possible outcomes for dendritic cells lacking a vital
gene. Either the loss of eEFlA2 is so devastating that the dendritic cells are ablated;
or, given its potential function in the control of the actin cytoskeleton, its loss results
in a deficit in motility or the maturation process in the dendritic cell and thus
hampers its proper functioning.
Ifwe turn to the literature however to see if there is any precedent for similar insults
to the dendritic cells causing the phenotype seen in wasted mice it seems unlikely
that what we see in wasted immune system could be attributable solely to the loss of
eEFlA2 in dendritic cells.
One study described the conditional ablation of dendritic cells in transgenic mice39.
Using HIV regulatory sequences that control preferential expression in dendritic
cells, mice were generated that expressed the HSV1-TK (Herpes Simplex Virus type
1 Thymidine Kinase) gene in dendritic cells. These mice were then treated with
ganciclovir which is toxic in dividing HSV1-TK positive cells. This method allowed
for the specific ablation of dendritic cells in the spleen and thymus such that 90% of
splenic dendritic cells were depleted in a week. Following this treatment these mice
exhibited major cortical atrophy of the thymus mainly due to the disappearance of
CD4+CD8+ thymocytes. However there was no gross modification of spleen
architecture39.
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In another study it has been found that patients with Wiskott-Aldrich syndrome, an
X-linked recessive disorder, have intrinsic dendritic cell abnormalities40. This is due
to the loss of function of the WASp protein due to mutations in the gene. WASp is an
intracellular protein expressed exclusively in haematopoietic cells and is thought to
regulate cytoskeletal architecture through the Rho family member TNK241. Here,
rather than loss of dendritic cells, the lack of functional WASp results in peripheral
blood-derived dendritic cells that are rounded in appearance with actin abnormally
distributed in perinuclear and subcortical regions. This results in dendritic cells that
mature but cannot translocate. Given eEFlA2's potential for cytoskeleton
interaction, this phenotype could be possible in dendritic cells lacking eEFlA2 -
however the clinical aspects ofWiskott-Aldrich syndrome are immune deficiency,
eczema and microthrombocytopaenia. Similarly young WASP-deficient mice
showed mild thrombocytopaenia and lymphopaenia as well as defective T cell
activation but no major atrophy or apoptotic defects42.
These studies seemed to suggest that it was unlikely that the loss of eEFl A2 in
wasted dendritic cells could explain the complete phenotype of the wasted immune
system.
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1.4 Identification of a novel gene
The mechanism by which the lack of a translation elongation factor in dendritic cells,
which comprise only a small percentage of lymphocytes, could result in the type of
chromosome damage observed in the lymphoid tissue ofwasted mice was unclear.
It was important to remember therefore that the wasted genotype was not a targeted
Eefla2 knockout but rather a classical mutation - a 15.8kb deletion. It therefore
seemed important to question whether or not there were other genes affected by this
deletion.
As addressed before there were no known or predicted genes within the wasted
deletion and so it was possible to surmise that Eefla2 was the only gene directly
affected in that its promoter and first exon were removed. However given the size of
the deletion there could have been more subtle position effects on neighbouring
genes. An enhancer or silencer element could have been removed by the deletion in
wasted mice or the deletion could have changed the local chromatin environment
such that the protein factors required for gene expression could no longer access such
elements. This type of effect on a neighbouring gene could result in an
increase/decrease in expression, ectopic expression or incorrect timing of expression
of this gene. In this way even though the gene itself would not be mutated, there
could be extensive pathology associated with its misexpression. There are many
examples of human disease caused by position effects where the genetic lesion can
be lOkb to 900kb away from the gene43
In order to address this possibility, it was important to take account of the genes
surrounding the wasted deletion. The three known genes close to the wasted deletion
did not present themselves as likely candidates for the immune system deficits in the
wasted mouse. Kcnq2 produces a voltage-gated potassium channel that is only
expressed in the brain44. It is found to be mutated in Benign Familial Neonatal
Convulsion (BFNC), a common epilepsy with autosomal dominant inheritance. In
mice, Kcnq2 knockouts die a few hours after birth of pulmonary atelectasis with no
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evidence of brain abnormalities while Kcnq2 heterozygotes display a hypersensitivity
to a seizure-inducing agent pentylenetetrazol45. Ptk6 produces a protein tyrosine
kinase whose expression is confined to the skin46 and gut47. There are no known
phenotypes associated with loss of function ofPtk6.. Srms produces a Src-related
kinase which is ubiquitously expressed but Srms'1' mice have no phenotype48.
Meanwhile, closer than these three known genes, the careful sequencing of the
region which allowed our group to elucidate the nature of the wasted genotype
uncovered a predicted gene approx lOkb from the wasted deletion. This gene
appeared to be completely novel.
Given what was known about Eefla2, the function of dendritic cells and the features
of the surrounding genes, I decided that the best course of action to elucidate the
origins of the immune system phenotype was to use this novel gene as my prime
candidate. The disadvantage of this course of action was that the gene and protein
would have to be characterised and tools (such as antibodies) acquired to analyse its
expression. However I felt that not only was this the best candidate but also its
novelty meant that my characterisation of it would be important whether it turned out
to play role in the wasted phenotype or not, while the other genes and proteins were
well-characterised.
Ptk6 Srms




Figure 1.4 Genes surrounding the wasted deletion. While there are a number of known
genes in the vicinity of the wasted deletion in addition to Eef1a2, none presented
themselves as good candidates for the immune system phenotype of the wasted
deletion. The gene closest to the wasted deletion other than Eef1a2 was a novel
undescribed gene.
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1.5 Aims
The aim of this thesis therefore was to characterise this novel gene with a view to
determining any role it played in the pathology of the wasted mouse. To do this I
intended to:
• confirm its transcription to mRNA and translation to protein
• analyse its expression patterns in the body and in the cell
• assess its function through silencing the gene in mammalian cell culture
During the course of this work I aimed to have acquired the tools and knowledge to
then examine the expression and function of this gene in wasted mice.
However, I could not neglect the potential that it was the loss ofEefla2 expression
alone that was responsible for the whole of the wasted phenotype. To examine this
possibility I hoped to analyse a set of transgenic animals in production by our group
at the time of beginning this project that would determine the role ofEefla2 in
wasted mice.
Chapters 3, 4 and 5 of this thesis describe the characterisation of the novel gene,
while chapter 6 looks at the role of this novel gene and Eefla2 in the wasted mice.
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CHAPTER 2
MATERIALS AND METHODS
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2 Materials and Methods
2.1 Materials
2.1.1 General reagents
Unless otherwise indicated, general laboratory chemicals were obtained from Sigma.
All PCR primers were from Sigma-Genosys or Invitrogen and cell culture media and
supplements were obtained from Invitrogen.
2.1.2 Buffers and solutions
Recipes for those buffers and solutions not described in detail in the text are as
follows:
10X Laemmli Running Buffer 250mM Tris HCI (pH 8.3), 1.9M Glycine
10% SDS
10X MOPS 200mM MOPS, 50mM sodium acetate
20mM EDTA, pH 7
20X SSC 3M NaCI, 300mM sodium citrate, pH7
2X Laemmli Loading Buffer 60mM Tris HCI (pH 6.8), 2% SDS,
0.1% bromophenol blue, 10% glycerol
Bejerrum & Schaefer-Nielsen Buffer 48mM Tris, 39mM Glycine, 20% MeOH
0.0375% SDS
ELISA OPD Buffer 0.493% w/v citric acid, 1.42% Na2HP04, pH
5
ELISA Plate-coating Buffer 0.195% w/v Na2C03, 0.293% w/v NaHC03
0.02% w/v sodium azide, pH 9.6
ELISA Wash Buffer 0.8% w/v NaCI, 0.02% w/v KH2P04, 0.114%
w/v Na2HP04, 0.02% w/v KCI, 0.5%
Tween®-20, pH 7.4
Mowiol 7.5g of Mowiol 4-88® (Sigma) was mixed
with 10ml glycerol in a 250ml flask. 25ml of
dH20 was added and the flask covered and
left at room temperature overnight. 50ml of
0.2M Tris HCI (pH 8.5) was added and the
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mixture heated in a boiling water batch for
20 minutes. The mixture was allowed to
cool before adding 1.75g of DABCO
(Sigma), an anti-fade agent and then mixed
until dissolved.
Northern Detection Buffer 0.1M Tris HCI, 0.1M NaCI pH 9.5
Northern Blocking Buffer A 1:10 solution of the blocking solution
provided by the manufacturer (Roche) in
0.1M maleic acid, 0.15M NaCI adjusted with
NaOH (solid) to pH 7.5
Northern Washing Buffer 0.1M maleic acid, 0.15M NaCI, pH 7.5,
0.3% Tween®-20
PBS (Phosphate Buffered Saline) 1 PBS tablet (Sigma) was dissolved in
200ml of dH20 and autoclaved
PBS-T (Phosphate Buffered Saline -
Tween®-20)
As above but following the autoclave step
0.1% (v/v) of Tween®-20 (Sigma) was
added.
Ponceau S 0.5% (w/v) Ponceau S, 2% (v/v) Acetic Acid
RIPA 150mM NaCI, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris HCI
pH 8.0
RNA gel loading buffer 50% v/v formamide, 0.166% v/v
formaldehyde, 10% v/v 10X MOPS, 10%
glycerol, 0.02% 2.5% bromophenol blue,
0.005% (v/v) ethidium bromide, 0.109%
(v/v) DEPC-treated dH20
TBE (Tris Borate-EDTA) 108g of Tris base, 55g of Boric acid and
9.3g of Na4EDTA were added to 1L of
dH20. pH 8.3 with no adjustment.
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2.2 Methods
2.2.1 RT-PCR
2.2.1.1 RNA preparation from tissues or cell lines
RNA from both frozen tissue samples and cultured cell lines was extracted using the
RNeasy Mini Kit (Qiagen) according to manufacturer's instructions.
2.2.1.2. DNase I treatment of RNA
RNA prepared as described above was subsequently treated with a DNase I enzyme
to remove any contaminating genomic DNA. This was accomplished using the
DNA-free Kit™ (Ambion) according manufacturer's instructions.
2.2.1.3 First strand cDNA synthesis
cDNA was prepared from isolated RNA by using the Retroscript® Kit (Ambion)
according to manufacturer's instructions
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2.2.1.4 PCR primers
Primers used to amplify portions of a range of genes were as follows:





















These were designed across introns by and large in order to ensure that any genomic
DNA contamination could be recognised easily.
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2.2.1.5 PCR
The following components were added to sterile Eppendorf tubes on ice.
10X Sigma reaction buffer 3pl
10mM stock dNTPs 0.6jd
Forward primer (18pmol/pl) 1pl
Reverse primer (18pmol/jd) 1pl
dHzO 21.1 pi
Sigma Taq polymerase (5U/pl) 0.3pl
DNA template 3j.il
Total 30pl
This reaction was then placed in a PTC-225® thermal cycler (MJ Research) set to
the following programme of incubations; 94°C for 3 minutes, then 94°C for 30
seconds, 58°C for 30 seconds, 72°C for 30 seconds these three incubations were
repeated for 29 cycles and finally 72°C for 10 minutes.
2.2.1.6 Agarose gel electrophoresis
The PCR products were separated and assessed by gel electrophoresis. This was
accomplished by making a 0.8% - 2 % (w/v) agarose solution in 0.5x TBE and
heating until the agarose had dissolved. Once the solution had cooled slightly, but
was still molten 0.003% ethidium bromide was added to the agarose solution and the
mixture as poured into a casting tray with suitable sized comb to set. Once set, the
tray was placed in a gel electrophoresis rig. The Ready Load™ lkb DNA ladder
(Invitrogen) and samples ofPCR products added to the wells in the agarose. The gel
was then typically run at 100V for 1 hour. The PCR products could then be viewed in
the gel under UV light.
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2.2.2 Northern blotting
2.2.2.1 Production of probes
The DNA template was linearised at a restriction site downstream of the cloned
insert in order to avoid transcription of undesirable sequences using a restriction
enzyme that left 5' overhangs or blunt ends. The DNA was then purified by
phenol/chloroform extraction, followed by ethanol precipitation.
The probes were labelled with DIG (digoxigenin) using the DIG Northern Starter Kit
(Roche) according to the manufacturer's instructions.
The RNA produced during the reaction was then DNase I treated to remove template
DNA; 2pi ofRNase-free DNase I was added and the reaction was incubated for 15
minutes at 37°C. The reaction was stopped by adding 2pl of 0.2M EDTA (pH 8) and
a small sample ofRNA product run on an agarose gel to check the size and purity of
the probe.
The efficiency of labelling was determined by carrying out serial dilutions of the
DIG-labelled probe and then applying the dilutions to nylon membrane. This was
also done with the supplied DIG-labelled control of known concentration.
2.2.2.2. Phenol/Chloroform extraction
An equal volume ofphenol:chloroform:isoamyl alcohol (25:24:1) was added to the
nucleic acid sample in a polypropylene tube. The contents of the tube were mixed
well by gentle inversion, until an emulsion formed. The organic and aqueous phases
were then separated by centrifugation at 12,000g for 5 minutes. The aqueous phase
(upper layer) was then carefully removed with a large-bore pipette, and the interface
and organic phase discarded. The phenol:chloroform:isoamyl alcohol extraction was
repeated until no protein (cloudy, white precipitate) was visible at the interface. To
remove traces of phenol, the nucleic acid solution was then extracted with an equal
volume of chloroform:isoamyl alcohol (24:1) in exactly the same manner.
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2.2.2.3 Ethanol precipitation of DNA
The volume ofDNA to be precipitated was measured, and the salt concentration
adjusted by adding 1/4 volume of 10M ammonium acetate (final concentration
2.5M). After mixing well, 2 volumes of ice-cold 100% ethanol were added and the
solution was mixed again. The DNA was then allowed to precipitate at on ice for 30
minutes. It was then pelleted by centrifugation at 12,000g for 15 minutes. The DNA
was then washed twice in 70% ethanol and allowed to air dry. Finally the DNA was
resuspended in an appropriate volume of dFhO.
2.2.2.4 Ethanol precipitation of RNA
To 20pl ofRNA, 2.5pl 4M LiCl and 75pi EtOH were added and incubated at -20°C
for 2 hrs. This was then centrifuged at 16000g for 10 minutes. The solution was then
washed in 70% EtOH (in DEPC dH20) and allowed to air dry. The pellet was then
resuspended in lOOpl DEPC dH20 and lpl RNase inhibitor and incubated for 1 hour
on ice and then vortexed and incubated at -20°C overnight as this aids resuspension.
2.2.2.5 RNA gel electrophoresis
First the gel rig was sterilised with 10% SDS in DEPC-treated water and 100%
ethanol. The gel was then prepared as follows:
3.6g of agarose were added to 255ml ofDEPC-treated water and the mixture heated
until the agarose had melted. This was then allowed to cool to approximately 60°C
before adding 28.38ml of 10X MOPS and 16.2ml of 37% formaldehyde in a fume
hood. This gel was then poured and allowed to set for at least 30 minutes at room
temperature. 20pl of loading buffer was added to the RNA samples and then
incubated at 65°C for 10 minutes and 4°C for 1 minute. The gel was pre-run at 30V
in IX MOPS buffer. The RNA samples were then loaded and the gel run at 125V for
1 -4 hours.
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2.2.2.6 Northern blotting
The RNA gel was trimmed and photographed with a ruler before incubating it in
DEPC-treated water for 15 minutes agitating at room temperature and then in 20X
SSC for 15 minutes agitating at room temperature. The RNA gel was then placed on
a wick of filter paper soaked in a bath of 20X SSC, nylon membrane placed on top
then three sheets of filter paper on top of that and finally a wad ofpaper towels
pressed down by a suitable weight to aid blotting. This was blotted overnight. The
membrane was then removed from the blotting apparatus, placed on 2X SSC-soaked
3MM paper and UV cross-linked. The membrane was then rinsed in DEPC-treated
water and allowed to air dry.
2.2.2.7 Hybridisation
The membrane was pre-hybridised in 20ml ofDIG Easy Hyb solution (Roche) in a
roller bottle at 68°C for 1 hour. 800ng ofRNA probe was then denatured by boiling
for 5 minutes and chilling on ice. The probe was then added to 8ml of fresh DIG
Easy hybridisation fluid and the pre-hybridisation fluid replace with the hybridisation
fluid containing the probe. The membrane was incubated in this at 68°C overnight.
2.2.2.8 Stringency washes and signal detection
The membrane was removed from the hybridisation fluid and washed in 2X
SSC/0.1% SDS twice for 5 minutes each at room temperature and then in 0.1X
SSC/0.1% SDS twice for 15 minutes each at 68°C. The membrane was then
incubated in washing buffer for 5 minutes and then blocking buffer for 1 hour. The
anti-DIG antibody (Roche) was added to Northern blocking buffer and the membrane
incubated in that for 30 minutes. The membrane was washed three times for 15
minutes each in Northern washing buffer. The membrane was then incubated in
Northern detection buffer for 5 minutes and then incubated in CPD-Star (Roche) for
5 minutes. The membrane was then sealed in a plastic bag with the CPD-Star,
exposed to X-ray film for 30 minutes and then the film developed.
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2.2.3 Preparation and purification of anti-peptide antibody
2.2.3.1 Design of peptide to be used as an immunogen
The PIX (Protein Identify X) suite of programmes at the HGMP (Human Genome
Mapping Project - www.hgmp.mrc.ac.uk) includes a programme that predicts the
antigenicity of portions of the protein under investigation. This was used to design
the peptide sequence that would be chemically synthesised and conjugated to KLH
(Keyhole Limpet Haemocyanin) by Graham Bloomberg at the University ofBristol
and subsequently used as an immunogen in sheep at Diagnostics Scotland. The
peptide sequence chosen was IPSSGSLVATHDY.
2.2.3.2 Confirmation of antibody specificity by ELISA
Peptide was dissolved in dH20 to a final concentration of 5 mg/ml. This was then
used to make serial dilutions of peptide; 5pg/ml, 1 pg/ml, 0.5 pg/ml, 0.1 pg/ml,
lOng/ml and lng/ml. 200pl of each dilution were added to 12 wells of an ELISA
plate (Nunc). This was then incubated overnight at 4°C. The wells were then washed
three times with ELISA wash buffer before being blocked by (freshly prepared) 1%
BSA in ELISA wash buffer and incubated for 1 hr at room temperature. The wells
were then washed three times. The primary anti-peptide antibody was then diluted to
1:100, 1:1000, 1:10000 and 1:50000 in ELISA wash buffer and added to the wells
for 1 hour at room temperature. The wells were again washed three times. The
secondary antibody was then added, diluted in ELISA wash buffer (1:1000) and
incubated at room temperature for lhr. The wells were again washed three times.
One lOmg tablet ofOPD substrate (Sigma) was then added to 25ml of OPD buffer
with 1 Op.1 of 30% hydrogen peroxide and added to each well. The absorbance of the
reaction was measured by spectrophotometer at 450nm.
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2.2.3.3 Ammonium sulphate precipitation of anti-Clwd antibody
The volume of the anti-serum was determined before centrifuging it at 3000g for 30
minutes. While the anti-serum was stirring gently 0.5 volumes of saturated
ammonium sulphate solution was added slowly in a drop wise fashion. Once added
the solution was transferred to 4°C and allowed to stir for 6 - 16 hours. The solution
was then centrifuged at 3000g for 30 minutes and the supernatant recovered. The
addition of 0.5 volumes of saturated ammonium sulphate to the supernatant was
repeated as before and allowed to stir again for 6-16 hours at 4°C. This was then
centrifuged at 3000g for 30 minutes, following which the supernatant was removed
and discarded and the pellet resuspended in 0.3-0.5 volumes of PBS, avoiding
frothing. This was then dialysed versus three changes ofPBS overnight
2.2.3.4 n-Octanoic acid precipitation of anti-Clwd antibody
The volume of the antiserum to be fractionated was measures and 2 volumes of
0.06M acetate buffer pH4.0 was added and allowed to stir. For each 100ml of anti¬
serum, 7.5ml of n-octanoic acid was added slowly drop wise and allowed to stir for a
further 30 minutes following the addition. The precipitate formed was removed by
centrifuging the mixture at 2000g for 20 minutes at room temperature. The
supernatant was recovered and filtered before dialysis against 0.154M sodium
chloride to remove the n-octanoic acid.
2.2.3.5 Immunoaffinity purification of anti-Clwd antibody
The ammonium sulphate or n-octanoic acid precipitated anti-serum was further
purified by running through an immunoaffinity column. These were obtained from
Pierce Biotechnology as a SulfoLink Kit with the purification being carried out as
per manufacturer's instructions.
Chapter 2 Materials and Methods 35
2.2.4 Western Blotting
2.2.4.1 Preparation of protein extracts
In order to extract protein from tissue samples, the tissue was homogenised in 0.32M
sucrose, with Complete Protease Inhibitor Cocktail (Roche) added to protect against
extract degradation. For cell lines, the cell pellets were resuspended and vortexed in
RIPA buffer also supplemented with protease inhibitors
2.2.4.2 Quantitation of protein
This was carried out using the Bio-Rad DC Protein Assay Kit following
manufacturer's instructions
2.2.4.3 Preparation of SDS-PAGE gel
The casting plates from Bio-Rad Mini PROTEAN 3 mini-gel set were assembled.
The 12% separating SDS-PAGE gel was then prepared as follows:
30% acrylamide 12ml





This was then poured between the plates leaving a 2cm space at the top for the
stacking gel. The separating gel was overlaid with isopropanol to avoid bubble-
formation and allowed to set for 30-45 minutes.
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The isopropanol was decanted and the stacking gel prepared as follows:
30% acrylamide 1.45ml





The stacking gel was then poured between the plates to the top and the combs
inserted at a 45° angle to avoid trapping air and pressed down firmly. This was then
allowed to set for 15-30 minutes.
The plates were then placed into the gel tank apparatus, the inner chamber between
plates filled with IX Laemmli running buffer and the outer chamber half-filled. The
combs were then removed and any acrylamide present in the wells was washed out.
The protein extract samples were then treated with lpl 1M DTT/lOpl of sample and
equal volume of2X Laemmli loading buffer. This was boiled for 5 minutes and then
loaded into the wells of the SDS-PAGE gel. A set of Pre-stained SDS PAGE
Standards, Broad Range (Bio-Rad) was also run to assess protein size. The gel was
run at 100V as the dye front progressed through stacking gel and increased to 150V
once dye front had entered separating gel.
2.2.4.4 Western blotting
Filter paper, HybondrM-P membrane (Amersham Pharmacia Biotech) and the SDS-
PAGE gel were soaked in Bejerrum Schafer-Nielsen transfer buffer. The filter paper
then Hybond™-P membrane then the gel and then another piece of filter paper are
placed on the semi-dry blotter. The gel was blotted at 15V for 1 -2 hrs. The
membrane was then stained in Ponceau S for 2 minutes, with the excess stain washed
off with dELO in order to visualise the transferred proteins.
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2.2.4.5 Detection of signal
The non-specific sites on the protein-containing membrane were blocked by agitating
the membrane in 5% powdered milk in PBS-T overnight at 4°C. The membrane was
then washed twice for 5 minutes each in PBS. The primary antibody was added to a
fresh milk solution and used to incubate membrane for 2 hours agitating at room
temperature. The membrane was washed 4 times for 5 minutes each in PBS-T. This
was repeated with secondary antibody for 1 hour agitating at room temperature and
then washed in PBS. Finally the membrane was either incubated in ECL™ solution
(Amersham Pharmacia Biotech) for 1 minute, exposed to X-ray film and developed,
or incubated in DAB (Sigma) for several minutes until the desired depth of colour
change had taken place and the membrane was washed in dE^O to stop the reaction
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2.2.5 Maintenance of cell lines
2.2.5.1 Thawing of frozen vials of cells
Vials were removed from liquid nitrogen and carefully placed in a 37°C water bath
to thaw - taking care in case any liquid nitrogen had penetrated the vial as this can
cause the screw cap to explode off when vial is heated. Once thawed, the cells were
added to 15ml ofmedium in a T75 flask that had been at 37°C and 5% CO2 for at
least 15 minutes. The flask was then returned to the incubator at 37°C and 5% CO2.
2.2.5.2 Subculturing of cells
Cells were passaged by first aspirating the growth medium from the flask/plate. 3ml
of trypsin:versene (1:1) was added to wash out any remaining medium and then
aspirated. A further 3ml of trypsin:versene was added and the flask placed at 37°C
for approximately 3-5 minutes until the cells had been detached from the plastic
(monitored by microscope). 7ml ofmedium was then added and the cells aliquoted to
the desired dilution in fresh flasks ofmedium. 15ml of growth medium was used in
T75 flasks/ 0.5ml in wells of 24-well plates.
2.2.5.3 Counting cells using a haemocytometer
The cells were trysinised and then lOOpl of the cell suspension is added to lOOpl of
Trypan Blue stain (Invitrogen). This mixture was then pipetted between the coverslip
and slide of the haemocytometer and examined under the microscope. The number of
cells (X) within the central square of the haemocytometer denotes the concentration
of cells i.e. X x 104/0.5ml. Any cells stained blue were dead.
Chapter 2 Materials and Methods 39
2.2.5.4 Cryopreservation of cell lines
Cells were trypsinised, counted and then resuspended drop wise in medium
supplemented with 5% DMSO to a final concentration of4 x 104 cells/ml and placed
in screw cap cryopreservation vials on ice. The vials were removed to a -70°C
freezer overnight and placed in liquid nitrogen the following day.
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2.2.6 RNAi
2.2.6.1 Design of siRNA duplexes
siRNA duplexes specific for Clwd were designed exactly as described in ref49.




Control (non-silencing) siRNA 5'-AATTCTCCGAACGTGTCACGT-3'
Vinculin 5'-AAGCGGATTAGAACCAATCTC-3'
2.2.6.2 Transfection of cell line
Cell lines were transfected with siRNA using two protocols. The first was exactly as
described by ref49 using Oligofectamine™ (Invitrogen), the second exactly as
described by the manufacturer's instructions of the RNAi Starter Kit (Qiagen). The
cells were examined for phenotype one, two, three and four days following
transfection.
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2.2.7 Immunofluorescent staining of cells
2.2.7A Fixing of cells
Cells were grown in 24 well plates on 13mm diameter coverslips (BDH). They were
fixed by aspirating off the growth medium, washing briefly in PBS and then
incubating in 0.2ml of an ice-cold 1:1 methanol:acetone mix at -20°C for 5 minutes.
The methanol/acetone was then aspirated and the cells washed in PBS three times
before proceeding with staining.
2.2.7.2 Immunostaining and counterstaining of cells
Once fixed, the cells were washed twice with PBS and then three times with PBS-T.
The cells were then incubated in a blocking solution (PBS-T/10% donkey serum/3%
BSA) for 1 hour before being incubated in the primary antibody diluted in the above
blocking solution for 1 hour. The cells were then washed three times in PBS-T before
being incubated in the appropriate secondary antibody, again diluted in the blocking
solution described, for 30 minutes. Following this, the cells were again washed three
times in PBS before the coverslip was removed from the well and mounted (cell-side
down) on SuperFrost® Plus microscope slide (Menzel Glaser) using Mowiol®
(Sigma) with a non-fade reagent added. The slides were allowed to air dry for 30
minutes before being wrapped in tin-foil and stored overnight at 4°C. The cells were
visualised the following day on an Axioskop 2 fluorescent microscope (Zeiss) and
using Smart Capture software
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2.2.8 Analysis of mouse stocks
2.2.8.1 Mouse strain
The wasted mutation arose spontaneously in the inbred HRS/J colony at the Mouse
Mutant Stocks Center of the Jackson Laboratory. The mutation was then crossed to a
segregating C3HeB/FeJ x C57BL/6J background.
2.2.8.2 Mouse husbandry
Mice were housed at the MRC Evans Building Transgenic Unit at the Western
General Hospital. They were fed on a standard chow diet. All mice euthanised were
done so by means of a carbon dioxide chamber.
2.2.8.3 Preparation of DNA from ear notches
For the purposes of identification and genotyping, mice were ear notched. The ear
notches were boiled in 0.6ml 50mM NaOH for 10 minutes, vortexed, neutralised
with 50pl Tris HC1 pH 8.0 and centrifuged for 6 minutes. The supernatant was
recovered and 1-3pi used in the genotyping PCR.
2.2.8.4 Genotyping of mice
Mice were genotyped by PCR in order to ascertain the presence of the wst allele, the
wild type allele and the BAC transgene or the PAC transgene
The PCR primers used were as follows.
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Wild type allele P2F 5'-TAGTGGCTCCTTGGAACAG-3'
P2R 5'-CTACTCTCCCTGAATGCCTT-3'
Wst allele Wstspan F 5'-ATAAGCTCCCCAATGGTAGAGAA-3'
Wstspan R 5'-CGCGCCATTCTTGTATTGTT-3'
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2.A Materials and methods appendix
2.A.1 SAGE (Serial Analysis of Gene Expression)
This section describes the method for gathering SAGE data. This data was queried in
chapter 3 to gain information on Clwd expression.
Serial Analysis of Gene Expression (SAGE) is a high throughput technique for
measuring gene expression profiles. Short cDNA tags (10-14bp) corresponding to
unique transcripts are isolated and concatenated into single molecules, allowing for
the simultaneous sequencing of thousands of tags. The relative tag abundance
estimated in the sequencing step reflects the transcription patterns of the
corresponding genes, allowing differential analysis of expression levels. How these
tags are acquired is explained below.
mRNA is harvested from the tissue and captured on oligo-dT beads. Double stranded
cDNA is then synthesized from the mRNA of the tissue or cells. This cDNA is then
digested with a frequently cutting restriction enzyme, the anchoring enzyme (AE),
with a 4-bp recognition site (usually Nlalll). A ligation reaction is performed which
attaches a linker to the 3' overhang of the digested cDNA. From 5' to 3' the linker
contains a primer sequence of either type A or B, a recognition site for a type IIS
restriction endonucleases (the tagging enzyme, TE), and a recognition site for the
AE. The nature of the TE will determine the length of the tag sequences obtained.
Short (10 base) nucleotide sequences are often sufficiently specific to discriminate
different transcripts from each other. The reaction is digested with the TE, which
cleaves DNA at a position 14-18 base pair (dependent on the enzyme chosen) from
its recognition site. This releases the linker along with short tags from a defined
position within each of the mRNA transcripts, namely 3' of the AE restriction site
closest to the Poly-A site. Pools of tag-linker oligonucleotides are ligated and
subjected to a PCR reaction. The amplified products contain two tags (ditags)
bordered by linker DNA. The linker DNA is removed from the ditags by a AE-
digest. The obtained fragments are ligated together to form a concatemer of tags
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which are cloned into a standard plasmid vector and sequenced. Concatenated arrays
are combined to form SAGE "libraries". The number of times a particular tag is
detected in a library gives a digital measure of the abundance of its associated










The siRNA User Guide http://www.rockefeller.edu/labheads/tuschl/sirna.html
HGMP www.hgmp.mrc.ac.uk
Ensembl www.ensembl.org
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IN SILICO STUDY OF THE NOVEL GENE CLWD
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3. In Silico Study of the Novel Gene Clwd.
3.1 Introduction
Clwd or Close to Wasted Deletion was originally discovered upon sequencing a
BAC carrying genomic sequence from the region ofmouse chromosome 2
surrounding Eefla2 and the wasted deletion. Having using this sequence to query the
Unigene EST database, a large cluster was found that correlated directly to sequence
approx 1Okb from the deletion. In addition, it was clear from the genomic sequence
that there was a CpG island upstream of the sequence matching the EST cluster. As
discussed previously, it was unclear how Eefla2 could be responsible for the
phenotype, seen in the literature, in the immune system of the wst/wst mice. It had
therefore become apparent that studies into the genes surrounding the wasted
deletion would have to be undertaken to look for a potential second candidate gene.
Previous work suggested that none of the other known genes in the region were
affected in the wasted mouse44'46_48, and so it was a case of searching for hitherto
unknown and uncharacterised genes. It was in this search that Clwd was discovered.
It was known already that no predicted gene existed within the deletion other than
the portion ofEefla2 already described and so this potential gene was the closest to
the deletion other than Eefla2. It thus made an excellent choice for an initial study.
This initial study took the form of a bioinformatic approach to gain as much
information as possible from the various tools, databases and other resources
available on the internet. In this chapter I will describe this in silico work as an
introduction to Clwd and its potential characteristics.
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3.2 From EST to novel gene
3.2.1 Clwd in the EST database
The presence of ESTs or Expressed Sequence Tags can be the first hint of the
presence of a novel gene as they represent the expression of the genomic DNA. On
examining the genomic region in the vicinity of the wasted deletion, it became clear
that there was a small region about 20kb upstream of the Eefla2 gene that was highly
represented in databases such as Unigene at NCBI which groups ESTs that share
sequence into clusters that may represent an, as yet, undiscovered novel gene. This
was done before the mouse genome sequence was available, or the advent ofmouse
genome browsers such as that at Ensembl (www.ensembl.org) and so the
identification of this candidate gene was accomplished through careful sequencing
and BLAST searches of the EST data available. I shall refer to this potential gene as
"Clwd" standing for "Close to the Wasted Deletion".
Within this EST cluster (now termed Mm.213943) at Unigene, it was clear that
despite there being significant identity between individual sequences (enough to
allow them to be confidently clustered together as representing one gene) there were
some sequence differences. This took the form of short stretches e.g. 80-200bp that
were seen in some ESTs and not in others. This suggested that if this was a bone fide
gene, then it was one that produced alternative splice forms. On closer examination,
it was clear that there were in fact five specific sequences that appeared again and
again.
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For the rest of this discussion I will refer to the following accession numbers as ESTs
that are representative of these 5 splice forms:






These are not isolated incidents of particular ESTs, but rather the most complete
sequence representing a set ofESTs. At The Institute for Genomic Research
(www.tigr.org) these sets are group into contigs with information regarding the
number ofESTs in each contig.
Splice form Representative EST TIGR Contig No. of ESTs
Splice form I AKO12037 TC1042785 37
Splice form II AK014211 TC1012538 53
Splice form III AK003282 TC1012537 40
Splice form IV AK002602 TC1012539 42
Splice form V AK012545 TC1012539 42
Despite the number of ESTs present in each contig it would still be very important to
prove their existence as true mRNAs biologically, given the unusual splicing. This
will be discussed in the next chapter.
It should also be noted at this stage that these ESTs came from a wide variety of
libraries from two-cell embryo through to adult and in a wide variety of tissues.
There appeared to be no strict correlation between splice form and tissue expression.
Therefore it seemed that if these ESTs did represent a gene it would be one that was
widely, if not ubiquitously, expressed from as early as the two-cell embryo. This
would, in turn, imply a gene with a vital function necessary for life at the cellular
level.
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Once the genomic sequence of the mouse became available for our region of interest,
it was possible to align these five ESTs with the genomic DNA sequence to see if it
had the necessary characteristics to be a gene. This was done using Spidey at NCBI
(National Center for Biotechnology Information) which also allowed me to assess
donor and acceptor splice sites at the stretches where the sequences differed between
ESTs, to see if they had the potential to be real mRNAs.
As can be seen from figures 3.2 and 3.3 below, these EST sequences are consistent
with the hypothesis that they represent alternative splice forms of a genuine gene,




















Figure 3.2a Output of NCBI's Spidey programme.
Alignment of ESTs representing Clwd splice forms with the genomic sequence
from chromosome 2 (Ensembl mouse release 19.32.2). It should be noted that
the sequences represented here are from the individual clones as named i.e.
the 5' ends of the true splice forms may not be exactly as shown.









Exon 1 186480-186590 1-111 111 d
Exon 2 186801-186872 112-183 72 d a
Exon 3 186945-187022 184-261 78 d a
Exon 4 187140-187236 262-358 97 d a
Exon 5 187318-187614 359-655 297 a
AK014211
Exon 1 186482-186590 1-109 109 d
Exon 2 186801-187022 110-331 222 d a
Exon 3 187140-187236 332-428 97 d a
Exon 4 187318-187642 429-753 325 a
AK003282
Exon 1 186478-186590 1-113 113 d
Exon 2 186686-186872 114-300 187 d a
Exon 3 186945-187022 301-378 78 d a
Exon 4 187140-187236 379-475 97 d a
Exon 5 187318-187640 476-798 323 a
AK002602
Exon 1 186431-186590 1-160 160 d
Exon 2 186686-187022 161-497 337 d a
Exon 3 187140-187236 498-594 97 d a
Exon 4 187318-187642 595-918 324 a
AK012545
Exon 1 186671-187022 1-352 352 d
Exon 2 187140-187236 353-449 97 d a
Exon 3 187318-187640 450-772 323 a
Figure 3.2b Output of NCBI's Spidey programme
Table showing relationship of EST sequences to genomic DNA including
splicing information.
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3.2.2 Clwd according to gene prediction programmes
With evidence that this region did harbour a gene I ran some gene-prediction
programmes on the genomic sequence in this region. One of the most valuable of
these was not just a gene-prediction programme, but in fact a means for running a
suite of packages over the same genomic region run at HGMP called NIX
(Nucleotide Identify X). These included programmes for predicting/displaying: CpG
islands, promoter regions, exons, genes, polyadenylation signal as well as BLAST-
hits to trEMBL, Swissprot and Unigene. NIX, however, does not just run one, but
several programmes available for each of the above functions allowing for increased
confidence of a correct prediction where more than one programme picks up the
same feature. See figure 3.4.
The output for Clwd confirmed the intron-exon structure I had surmised from
comparing the EST database to the genomic sequence available, which can be seen
by looking at the output for GRAIL, FGenes and GENSCAN in particular. These
programmes compare known ESTs to the genomic sequence. They did not recognise
the alternative splicing that I had noticed because these programmes only "see"
alternative splice forms represented by ESTs when the splicing takes the form of
skipped exons e.g. in EST1 exon A, B and C are present while EST2 has only exon
A and C. This would be called as an alternatively spliced exon. However the
alternative splice forms seen in the case ofClwd make use of alternative 5'and 3'
donor sites in the first two exons, and exhibit the retention of the second intron. This
type of splicing is not recognised by these programmes as it is more likely to be due
to a mistake in the alignment or in the ESTs. Although I had confirmed there was
more than one of each type of splice form represented in the EST database, this did
emphasise again the importance of following up this work with biological
experiments.
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To facilitate the process of identifying a potential new gene, NIX also provides
programmes to ascertain the presence of CpG islands, promoter sequences and poly
A tail leader sequences whose presence would make any gene prediction from EST-
genomic sequence alignment all the more sound.
For Clwd, NIX predicted these features as summarised below:
Feature Programme Quality of prediction






Poly-A Tail GENSCAN/polya Good
FGenes/polya Excellent
GRAIL/polya Good
While three of the five promoter prediction programmes found a promoter upstream
of the starting codon ofClwd, it is a little disconcerting that two programmes did not.
However, as the two programmes that did not find a promoter are usually used for
gene prediction only, I decided to try out some other internet-accessible promoter-
predictors. First I tried the Dragon Promoter Finder at The Institute for Infocomm
Research, Singapore (http://research.i2r.a-
star.edu.sg/promoter/promoterl_4/DPF.htm). This predicted a promoter sequence
upstream of the start codon with 65% sensitivity. The Neural Network Promoter
Predictor (www.fruitfly.org/seq_tools/promoter.html) gave a positive result also with
a score of 0.99. This score is related to the confidence of the prediction as shown.
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Threshold % promoters recognised False positives
0.99 10% 0.0%
0.97 20% 0.0-0.1%
0.92 30% 0.1 -0.3%
0.85 40% 0.1-0.4%
0.7 50% 0.8-1.0%
Having used these additional promoter-predictions I was more confident that there
was a real promoter to allow for the transcription of the gene.
This combination of confirming the intron-exon structure and predicting various
features of a gene model such as CpG island, promoter and polyadenylation sites
suggested that Clwd was a previously undescribed gene.
Another feature of Clwd I wanted to look at in a genomic context was to see if there
were any pseudogenes ofClwd that I could detect, and whether these were expressed
in any way, contributing to the EST data. Using the genomic BLAST service at
Ensembl I found that there were three areas of the genome with significant similarity
to the Clwd region of chromosome 2. These were located on the X chromosome,
chromosome 14 and chromosome 10. An overview of their location and an alignment
of these sequences are shown below.
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►Clwd gene^-Pseudogenes
Figure 3.5 Illustration of the position of the pseudogenes of Clwd in the mouse genome
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This alignment shows that the three pseudogenes shown are indeed processed
versions ofClwd lacking in introns. However, there are also deletions and mutations
in these versions of Clwd that means that none produce the same open reading frame
as Clwd. In addition, the open reading frame of each, shown below, when used as a
query of the mouse EST database in a tBLASTn search fails to find any EST with the














Figure 3.7 ORFs of Clwd and three pseudogenes on chromosome X, 14 and 10
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3.2.3 Open reading frames of Clwd ESTs
The next important stage of data mining the genomic sequence ofClwd was to look
at the potential protein produced by this gene. The open reading frame of Clwd can
be seen in figure 3.8. This figure also shows that the splice variants of Clwd produce
one of two types ofORF depending on whether or not the second intron is retained.
The other differences between the splice variants occur in the first exon and intron
that, in the case of Clwd lie in the 5' untranslated region.
The two types ofORF are essentially a full-length and truncated version of the same
open reading frame as a stop codon is present within the second intron
In addition to Clwd's main ORF, it also exhibits a short conserved upstream ORF as
shown in figure 3.9. This feature would not have been noticed had it not been
conserved through evolution. Upstream open reading frames are just beginning to be
understood. They appear to be important in the post-transcriptional control of gene
expression in that their presence can repress the translation of the main open reading
frame.
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Splice forms II, IV and V would produce
MAAIPSSGSLVATHDYYRRK*
Isoform I: AK012037 - Full Length CLWD
GGTGTGGGTC CTAAAGTGGT GTTTCGTGGG TTATCTTTGC AA ATG GGC TCC GCG GCC TAG
M G S A A *
CGCCCTGGTG GCCTAAAAAC GAAGCCTGCA AGGAAGGGGT TCTCCGCCGA GCGCCTCGGT
CCTGAAGC ATG GCA GCC ATC CCT
M A A I P
TCC AGC GGC TCG CTC GTG GCT ACC CAT GAC TAC TAT CGG CGA CGC CTG GGC TCC
S S G S L V A T H D Y Y R R R L G S
TCG TCC AGC AGC AGC TCC GGC GGA AGT GCC GAG TAC CCT GGG GAC GCC GTG CTC
S S S S S G G S A E Y P G D A V L Q
CAG TCC CCG GGT CTT CCC AAA GCC GAC CCG GGC CAC TGG TGG GCC AGC TTC TTT
S S P G L P K A D P G H W W A S F F
TTC GGG AAA TCC ACA CTC CCG TTC ATG ACT ACA GTG TTG GAG TCT CCT GAG CGC
F G K S T L P F M E S P E R S A E S
TCG GCA GAA TCC CCC CAG GTC TCC AGA AGC CCG ATG ACC TGT GGC CTG ACT CCT
P Q V S R S T T V L P M T C G L T P
GAA ACC ATG AAG CAG CAG CCA GTC ATC CAT TCT GGC CAG ACC AAC CCC AGG GAC
E T M K Q Q P V I H S G Q T N P R D
CTT TCC TGA
L S *
CCTATCAGAA TCTGCAGCCT GCCCAAGCTG AAGTGGTGCT AGGCCAGTGC CTACCCTCTC GACCCTCCCT
GTAAACTAGG AAGGCTGAAC AAGAGAAACC AGTAGAAGCT GGAGAGAGCC CCCTCTTGGT TCACAGCACT
GAACTTTCCT GACCCCATAA CTGTGTCTTG GCACAAAGC
Figure 3.8 The open reading frames produced by Clwd splice forms
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3.2.4 Conservation of Clwd through evolution
Another important piece of evidence in favour of Clwd being a true gene is the fact
that it is conserved from fish to human. We assume that DNA sequence that is
conserved through several species is important for normal function as otherwise,
over time, it would have accumulated mutations and/or become rearranged.
Therefore the fact that Clwd is present through several species is a sign of its having
a function important to those species. Clwd cannot be detected in either D.
melanogaster or C. elegans, thus it seems to be important to vertebrates only.
It can also be seen that the upstream open reading frame present in mouse is also
present in each of these species. While the sequence is well conserved in zebrafish,
xenopus, rat, mouse and human, the fugu sequence is quite different except for the
last position, which, while not the alanine of the other species, is isoleucine, another
hydrophobic residue.
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3.3 Identification of a potential role for Clwd
3.3.1 Potential characteristics of Clwd
Having determined the gene structure, splice variants and peptide sequence of Clwd,
the next step was to see what biological information could be gleaned from this raw
data.
With the peptide sequence, I used bioinformatic tools to get information on the
subcellular localisation, post-translational modification and/or conserved domains
that could give a clue as to the function ofClwd
First, I tried to localise Clwd to a particular cell organelle/compartment by using the
PSORT programme at HGMP. This assesses Clwd for the presence of various signal
sequences that are known to direct the location of known proteins. In order to get an
impression of the value of this prediction I used the peptide sequences of Clwd from
different species in this programme.
Cell compartment Human Mouse Rat Xenopus Zebrafish Fugu
(%) <%) <%) (%) (%) (%)
Nuclear 28 32 40 28 20 28
Cytoplasmic 16 32 24 24 24 24
Mitochondrial 40 20 20 36 44 36
Cytoskeletal 4 12 8 8 4 4
Vacuolar - 4 - - - -
Peroxisomal 4 - - - 4 4
Plasma membrane 4 - - - - -
ER 4 - - - - -
Secretory vesicular - - 8 4 4 -
Extracellular - - 4 - - 4
Although there is some agreement between the various species' Clwd subcellular
localisation, the predictions are far from definite, with nuclear, cytoplasmic and
mitochondrial all being quite close for each species.
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However another programme, Target P (http://www.cbs.dtu.dk/services/) gave the
following result:
Name mTP SP Other Location RC
Human 0.780 0.072 0.177 Mitochondria 2
Mouse 0.802 0.054 0.200 Mitochondria 2
Rat 0.755 0.053 0.217 Mitochondria 3
Xenopus 0.745 0.029 0.307 Mitochondria 3
Zebrafish 0.715 0.024 0.399 Mitochondria 4
Fugu 0.814 0.022 0.285 Mitochondria 3
mTP - mitochondrial targeting peptide
SP - signal peptide
RC - reliability class - measure of the size of the difference (diff) between the
highest (winning) and the second highest output scores
RC 1: diff > 0.800, RC 2: 0.800 > diff > 0.600, RC 3: 0.600 > diff > 0.400, RC
4: 0.400 > diff > 0.200, RC 5: 0.200 > diff
This suggests that Clwd is in fact mitochondrial for all species.
On consulting a third programme however, MitoProt II 1.0, which uses the sequence
of the protein to predict the probability of that protein being exported to the
mitochondria the results were as follows.







It can be easily seen from these results, therefore, that it is difficult to conclude
where exactly Clwd is located given that its sequence doesn't seem to have any of
the definitive patterns or signals that can be interpreted easily by computer
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programmes. All that can be said is that there is a chance that Clwd is expressed in
the mitochondria.
In addition to determining subcellular localisation, there are also many programmes
available that predict the presence of various forms ofpost-translational
modification. The post-translational modification of a protein has an important effect
upon characteristics such as subcellular localisation, function and interaction with
other proteins.
Phosphate, glycosyl or myristyl groups modify particular amino acids within a
peptide sequence. It is the context within which these amino acids find themselves
that dictates if the modification will occur. Programmes that predict these
modifications use this to calculate the probability that the amino acid is targeted.
One of the first programmes I ran on Clwd combined a signal peptide identifier,
which should predict ifClwd is exported out of the cell and thus more likely to have
modifications like glycosylation, and a glycosylation prediction programme. This
was the NetOGlyc 3.0 Server (http://www.cbs.dtu.dk/services/). This gave the



















Figure 3.10 Graphic output from NetOGlyc 3.0 programme predicting presence of
O- glycosylation sites in Clwd
NetOGlyc 3.0: predicted O-glycosylation sites in Mouse
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This shows the potential for O-glycosylation of each serine/threonine residue in the
sequence. Those lines that cross the threshold are more likely to be modified in vivo,
although in this case, these lines are not much higher than the threshold. This
programme also looked for a signal peptide that it did not find in Clwd and so the
following accompanied the above result:
WARNING: This sequence may not contain a signal peptide!!
Proteins without signal peptides are unlikely to be exposed to
the O-glycosylation machinery and thus may not be glycosylated
[in vivo) even though they contain potential motifs.
SignalP-NN euk predictions are as follows:
Cmax Position ? Ymax Position Smax Position ? Smean ?
0.131 34 No 0.055 16 No 0.318 1 No 0.143 No
C-score raw cleavage site score
The output score from networks trained to recognise cleavage sites vs.
other sequence positions.
S-score signal peptide score
The output score from networks trained to recognise signal peptide vs. non-
signal-peptide positions.
Y-score combines the above to find the total cleavage site score
This suggests that Clwd is not O-glycosylated or, for the same reason, N-
glycosylated.
There is a form of glycosylation that occurs in nuclear and cytoplasmic proteins - this
is the modification of serine/threonine residues by O-linked N-acetylglucosamine.
This is a dynamic modification, more similar to phosphorylation than traditional O-
glycosylation. Considering Clwd is unlikely to have a signal peptide, this form of
modification is far more likely than traditional glycosylation, and indeed when I used
YinOYang 1.2 (http://www.cbs.dtu.dk/services/) the results confirmed this
likelihood.
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In addition to showing potential O-GlcNAc sites in a peptide, this programme also
runs "NetPhos" which predicts which serine/threonine/tyrosine residues will be
phosphorylated. As a result the residues that have the potential to be both
phosphorylated and O-GlcNAcylated are displayed. This is important as there are
proteins known to have both modifications at one site in their sequence and that these
are reversibly and dynamically modified at different times in the cell.
The raw output for Clwd is shown in the next figure. It can be easily seen that Clwd
could well be both phosphorylated and O-GlcNAcylated in vivo. In addition, on
comparing the sites modified on each species' Clwd, the first two regions of
modification occur in each, as well as a broad correlation in modification along the
length of the protein.
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Other post-translational modifications that could affect Clwd are GPI (glycosylated
phosphatidylinositol) anchors that attach proteins to the cell membrane; N-
myristoylation sites direct and anchor proteins to membranes and tyrosine sulphation
that occurs on proteins that go through the secretory pathway. Clwd is not predicted
to have any of these modifications using the primary sequence alone.
Using several other programmes (PredictProtein
http://cubic.bioc.columbia.edu/predictprotein/ and REP http://www.embl-
heidelberg.de/~andrade/papers/rep/search.html at EMBL) I discovered that Clwd is
unlikely to have transmembrane helices or repeats. The predicted pi and Mw for the
various forms of Clwd are as shown.







In addition to motifs for post-translational modification, the primary sequence of a
peptide can also have particular patterns or motifs that can designate some function
or potential interaction of the peptide. These include such things as DNA binding
domains, ATP binding domains, etc. I used the Prosite database of protein families
and domains at Expasy (www.expasy.ch) to scan Clwd for any domains that may be
present.
The patterns that were found were: N-glycosylation sites, Casein kinase II
phosphorylation sites, Protein kinase C phosphorylation sites, N-myristoylation sites
and ATP/GTP-binding site motifA (P-loop) with the following distribution.











Human Yes Yes No Yes Yes
Mouse No Yes Yes Yes Yes
Rat Yes No Yes Yes Yes
Xenopus No Yes Yes Yes Yes
Zebrafish Yes Yes Yes Yes No













However each of these patterns comes with the following note [Warning: pattern
with a high probability of occurrence]. This means the consensus sequence is short
and so the probability of it occurring in any sequence by chance is quite high. For
example we know already that Clwd does not have a signal peptide and so is unlikely
to be N-glycosylated and yet amotif that is glycosylated is simply NSSC-" a
sequence quite likely to occur by chance.
Also, because none of the myristoylation recognition sites are found at the N-
terminus of the protein we suspect that Clwd would not be modified by a myristyl
group at an internal recognition site.
One of the more interesting patterns here is the possibility that Clwd can bind
ATP/GTP. Up until the last version ofProsite, this pattern was not deemed as having
a high probability of occurrence. As ofDec 2003 however, this has changed and so
one must be wary of referring to Clwd as an ATP/GTP binding protein without
biological evidence. It is also worth noting that despite the sequence being well
conserved in that area between the fishes and higher vertebrates, there are enough
N-glycosylation
Casein kinase II phosphorylation
Protein kinase C phosphorylation
N-myristoylation
ATP/GTP-binding site
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changes for this area to no longer contain an ATP-binding site according to Prosite
i.e. "-ASFFFGKS-" is amotifbut "-SSFFFGKQ-" is not. It could be possible that
Clwd has acquired a different function in the higher vertebrates as sequence changes
result in the appearance of new functional motifs, or this ATP/GTP-binding site
could be a spurious result.
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3.3.2 Relationship to known proteins
Having used the programmes available to get some basic information about Clwd,
the next step was to use BLAST (Basic Local Alignment Search Tool) available at
NCBI, HGMP and Expasy to look for similar amino acid sequences held in the
Swiss-prot and trEMBL databases. I hoped this would show me ifClwd was similar
in any way to known proteins other than in the context ofwell-characterised
domains.
However when I use BLAST to search the protein databases, the only significant hits
are to Clwd itself in each of the species already described.
I also used PSI-BLAST that uses an iterative approach to identify more distantly
related proteins. Unfortunately this did not result in any more significant hits.
I therefore used a BLAST search available at NCBI that looks for short nearly exact
matches. Here, in addition to finding Clwd from other species I also came across
other hits. It is difficult to interpret these results. As they are short, good matches, an
example ofwhich is shown below, it could represent a pattern or domain that has yet
to be described. However it should also be noted that most of these matches occurred
in regions where the amino acid composition was somewhat skewed toward one
particular residue, and so what the BLAST search has really done is found serine, or
proline rich regions see Results [1], There were some non-biased matches though see
Results [2]
As can be imagined considering these could be new domains, the proteins that were
hit are not well described in the literature or databases and the subject sequence does
not represent any known domain.
Thus it seems that not only is Clwd a novel gene, but in fact a pioneer gene - unlike
anything already known.

























Figure 3.13 Results of using BLAST in "short nearly exact matches" format to look for Clwd
homology (multiple alignment in Clustalx colour).
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3.3.3 Where is Clwd important?
One of the newer tools available on the internet is one that can query the SAGE data
being generated at the NIH. SAGE or Serial Analysis ofGene Expression is a
technique that produces a quantitative profile ofcellular gene expression. For an in-
depth description of the method used in SAGE see chapter 2.A
Essentially, the SAGE technique quantifies a "tag" which represents a gene
transcript. A tag, for the purposes of SAGE, is a nucleotide sequence of a defined
length, directly 3'-adjacentto the 3-most restriction site for a particular restriction
enzyme. By being able to find the tag representing a gene of interest and using that
to query the database, one can obtain a "virtual Northern blot" of the gene. As this
database was originally set up as part of the Cancer Genome Anatomy Project it is
also possible to compare the expression of a human tag/gene in normal and
cancerous tissues and/or cell lines.
Both human and mouse Clwd are represented by tags in this database and so I could
obtain a description of Clwd gene expression using SAGE, see figure 3.14a, b and c.
This again shows the wide expression suggested by the EST database with Clwd seen
in the mouse brain, heart, liver, testis, spleen, limbs and skin; as well as ES cells,
embryonic carcinoma cells, T cells and dendritic cells. Expression seems particularly
high in the fore and hind limbs, a CD4+ T cell line and liver.
As for the human cancer genome information, there appears to be an increase in
Clwd expression in tumours of the breast, prostate, stomach, pancreas, peritoneum
and glioblastoma. It is worth noting that Clwd lies on human chromosome 20 at
20ql3.3. 20ql2-13 amplifications are found frequently in ovarian tumours associated
with poorer survival and a more aggressive tumour pathology and in a variety of
other solid tumours, most notably breast and colorectal cancer.
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Figure 3.14a Output from SAGE at NCBI for tag representing mouse Clwd - Virtual Northern








































Figure 3.14b Output from SAGE at NCBI for tag representing human Clwd
Normal vs. Cancer expression.
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SAGEBrainAnatomicViewerResults
Searchquery:ACCGCCTGTG,Tissuesandc lllines NORMALCANCER




On comparing the sequence of the ESTs that represent Clwd, with the genomic DNA
sequence at the telomeric end ofmouse chromosome 2, it became clear that Clwd
was a slightly unusual gene. It is 1.2kb in length, with 3-5 exons and introns of
between 72bp and 209bp in size; given the average mouse intron is 3,888bp in length
and the mean number of exons per transcript is 8.450, Clwd is unusually small. Does
this have any implications for Clwd function? On examining the intron size of a gene
with its level of expression it has been found that in mammals at least, introns in
highly expressed genes are substantially shorter than those in genes that are
expressed at low levels as short introns minimize the slow and expensive process of
transcription and splicing51. This implies Clwd is a highly expressed gene in addition
to a widely expressed gene as suggested by the EST data.
Clwd is alternatively spliced like approximately 41% of all mouse genes50. The form
of alternative splicing seen in Clwd can be termed length difference alternative
splicing, or LDAS as it results in the deletion of a part of the predicted protein
sequence. LDAS can create dominant-negative regulators, with the short isoform
usually functioning as the regulator . In the case of Clwd this could mean that the
short form of the protein, if produced by splice forms II, IV and V, could regulate
one produced by I and III and so the relative abundance of the alternatively spliced
transcripts in any particular tissue could affect the normal function of Clwd.
There are processed pseudogenes present in the mouse genome that appear highly
similar to Clwd. Processed pseudogenes arise through retrotransposition of spliced or
partially spliced mRNA into the genome; they are often recognized by the loss of
some or all introns relative to other copies of the gene. They sometimes contain all
exons, but often have suffered deletions and rearrangements. Over time, pseudogenes
tend to accumulate mutations that clearly reveal them to be inactive, such as multiple
frameshifts or stop codons.
This has indeed occurred in the case of the Clwd pseudogenes. What is interesting is
that the three pseudogenes described seem to represent different stages in the
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accumulation of these mutations. The pseudogene on chromosome X is highly
similar to splice form I, with only a small deletion and subsequent change in frame
late in the sequence distinguishing the ORF from the "real" Clwd. The chromosome
14 pseudogene has an increased number of point mutations while the chromosome
10 pseudogene has a large number of point mutations. It is thus possible to surmise
that the retrotransposition event that created the chromosome X pseudogene occurred
most recently, with the chromosome 10 pseudogene being the oldest.
Clwd also exhibits an upstream open reading frame. This can dramatically influence
the translation of the main ORF. Only 10% of vertebrate mRNAs carry a uORF and
this population is largely biased toward proto-oncogenes and genes producing
growth factors and growth factor receptors.
An upstream open reading frame can play a major role in the expression of the main
protein-producing ORF. One example of this in mammals is the AdoMetDC gene
whose 5'UTR contains a six-codon uORF that represses translation of the main ORF
in T cells five-fold while in non-lymphoid cells there is little or no effect. Another
important aspect to this uORF-mediated translational repression is the gene
architecture surrounding the uORF i.e. the closer the uORF to the main ORF, it
seems, the more efficient the repression53.
So what does all this mean for Clwd? Although it is by no means decisive, the
presence of this uORF in the Clwd mRNA could mean it is a proto-oncogene, or a
gene that produces a growth factor or growth factor receptor. The fact that the 5'UTR
architecture changes with the different splice forms ofClwd could mean that if this
uORF is an inhibitor ofClwd translation, then this inhibition could vary with splice
form. In this way the relative abundance of each form in each tissue could affect the
abundance and thus function of Clwd gene product.
Using programmes to predict various biological features of Clwd has not been an
unqualified success. The subcellular localisation programme results are contradictory
and while amotif-based search may offer all the possible ways Clwd could be
modified, it is far from certain if these modifications occur in vivo. In addition the
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lack ofwell-defined domains and any homology to a known protein makes it all the
more difficult to begin to arrive at a possible function for Clwd.
However, given the nature of Clwd as an undescribed and apparent pioneer gene an
in silico study was the best way to start obtaining information and acquiring ideas
regarding the characteristics and function of this new and unusual gene. It revealed
where the gene lay, its sequence and protein product. This could be used to design
primers, antibodies and other biological tools to begin to characterise this gene. It
also identified interesting features that would be worth further investigation such as
an upstream open reading frame and the presence of alternative splice forms - are
they true biological features of this gene and what is their function, if any? It has also
given some clues as to Clwd's function. Does the presence of a uORF suggest a
growth factor? Does the apparent up-regulation of expression in some forms of
cancer suggest a role as an oncogene?
These bioinformatic tools proved useful in initiating a characterisation of the novel
gene Clwd as they provided a starting point for a series ofbiological experiments to
confirm their predictions. These are described in the following chapters.
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CHAPTER 4
CHARACTERISATION OF CLWD I:
EXPRESSION OF mRNA AND PROTEIN
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4. Characterisation of Clwd I: Expression of mRNA and
Protein.
4.1 Introduction
Having used bioinformatics to characterise Clwd as much as possible, I started in
vitro rather than in silico experiments. I decided that my first priority would be to
confirm that Clwd is genuinely being transcribed. I would do this by Northern blot.
Once this was done, the presence of any alternative splice forms could be ascertained
and subsequently the expression of these splice forms in mouse tissue could be
analysed by RT-PCR. Given the SAGE results discussed in chapter 3,1 also felt it
would be important to see if there was a difference in Clwd expression on comparing
normal to cancerous tissue.
Having confirmed the presence of Clwd mRNA in tissues, the next goal would be to
confirm that any Clwd was translated by designing an antibody against Clwd that
could be used in several applications including Western blotting and
immunocytochemistry.
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4.2 Expression of alternative splice forms of Clwd
4.2.1 Initial confirmation of splice form expression by Northern blotting.
I decided that the best way initially to confirm that Clwd is transcribed was to use a
Northern blot. IMAGE clones corresponding to Clwd ESTs were available from
HGMP and I used one of these (IMAGE 468225) as the template for making an
antisense Clwd probe (and a negative control sense probe). RNA was extracted from
various mouse tissues, including heart, spleen, liver and gut and these extracts were
run on a formaldehyde gel, before transferring them to a nylon membrane. I labelled
the RNA probe with digoxigenin or "DIG" as described in chapter 2 and hybridised
with the DIG-labelled Clwd RNA probe. The results are seen in figure 4.1.
Clwd was present in all tissues tested. This confirmed the wide range of expression
implied by the EST data. Interestingly, there was also evidence ofmore than one
band in each lane representing different sizes of Clwd mRNA transcript, i.e. different
splice forms. It appeared that there were three or four splice variants visible in some
of the tissues. An approximate idea of the size can be made by using the two rRNA
bands (4.712kb and 1.869kb) as a guide but otherwise it is difficult to accurately
ascertain the size and thus the identity of these bands.
The Northern blot provided the first concrete evidence that not only did the Clwd
gene produce detectable mRNA, but also mRNA that was alternatively spliced.
However, I believed it would be difficult to confirm the exact identity of these splice
forms by Northern blot alone and so elected to use RT-PCR to identify which splice
forms were expressed where.
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4.2.2 Distinguishing expression pattern of Clwd splice forms by RT-PCR
Having confirmed that there was at least some alternative splicing of Clwd in mouse,
I wanted to answer a number of questions. Were they as I had predicted from the
EST data? Was there any specificity with regard to their expression in various
tissues? Could I gain any insight into their relative abundance in tissues? I decided to
achieve this by RT-PCR by designing specific primers to distinguish the splice
forms.
The primers I used were Clwd A, B, C, D, E, F and "TotalClwd" (forward and
reverse) as described in chapter 2. These were designed to maximise the difference in
sequence between the splice forms predicted, while the product of the TotalClwd
PCR would be predicted to represent total Clwd expression as the primers were in
exons 4 and 5 which remain constant through all the splice forms. Where these
primers appear in relation to splice forms and genomic DNA are seen in figure 4.2.
The sizes of PCR product produced by each of these pairs of primers were as
follows. These primer sequences are described in section 2.2.1.4 in chapter 2.
Position of
primers
Exon 1-2 Exon 1-2 Intron 1-
exon 2











Splice form 1 - 65 - 120 450
Splice form II - 65 - 191 450
Splice form III - 180 - 120 450
Splice form IV 296 180 - 191 450
Splice form V - 156 191 450
While these primers did maximise the difference between the splice forms, I was
unable to design primers such that each splice form would give a unique band. I
could, however, distinguish splice forms IV and V. Splice form IV was the only form
that had a slightly larger first exon with sequence not present in the other splice
forms' exon 1 and so a primer designed to this (A) in conjunction with one further
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downstream (E) would identify it specifically. Splice form V retains a little more of
intron 1 than the others and so primer C was designed specifically to this region, and
so should not recognise anything other than splice form V.
It was more difficult to distinguish between splice forms I, II and III as there was no
feature unique to these forms that I could use to my advantage. In that case,
therefore, the best option was to distinguish between the splice forms that do and do
not retain part of intron 1 and likewise for intron 2. In particular I was interested in
the retention of intron 2 as this, I had predicted, had a short open reading frame
producing a truncated peptide and so it was of interest to see if the splice forms
producing this were as abundant as the others.
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The tissues used in the RT-PCR were from a 17 day old wild type mouse from the
wasted stock (see chapter 2 for strain details). The RNA was extracted and cDNA
prepared as described in chapter 2. The primers described were then used to amplify
regions of the cDNA to ascertain the splice forms present. Two types of control were
included. During the cDNA synthesis, for each RNA sample that was reverse
transcribed, another RNA sample from the same tissue was processed, except
without the reverse transcriptase that is vital to produce cDNA. This was necessary
to confirm that there was no genomic DNA from the tissues carried over during the
RNA preparation. If this control was negative for each sample, I would know that all
PCR products seen in the reverse transcribed samples were derived from mRNA
rather than contaminating DNA. Bearing in mind that there were three pseudogenes
identified for Clwd (chapter 3) this control was particularly important.
The second was a PCR control, where for each set of primers (and thus master mix)
one sample to be amplified by PCR contained no DNA template. This would ensure,
given a negative result for this sample, that there were no contaminating PCR
products or other sources ofDNA template for the PCR present in the components of
the reaction.
The results of the RT-PCR are shown in figure 4.3











Figure 4.3 Results following the RT-PCR of various mouse tissues using primers A, B, C,
D, E, F and TotalClwd. The seguences of these primers can be found in section
2.2.1.4 of chapter 2. The sizes of PCR product denote the types of splice form
present in each tissue (see table on page 98 for information). Here Gapdh
primers were used to amplify the housekeeping gene Gapdh as a control for the
RNA and thus cDNA levels in the samples used
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There were a number of points to be noted about this experiment.
Firstly, the lack of bands in the negative controls, both the RT negative and PCR
negative control, suggested that the bands seen in the lanes representing the tissue
samples did truly represent the amplified portions ofmRNA, and not any form of
contamination.
Secondly, it can also be seen that there were extra bands in both PCR A-E and PCR
B-E that were not predicted to be produced by the 5 known splice forms. When these
were examined more closely it could be seen that the extra band in PCR B-E is larger
than the predicted bands of 180bp and 65bp in length. Given that the band is quite
faint and that there are two products produced by this PCR it is most likely that this
band is due to the formation of a heteroduplex. This is where one strand of one
product anneals with one strand of another at their compatible 5' and 3' ends with a
loop of their non-compatible sequence in the middle. Bands such as these are
retarded in their progress through the gel and so they appear larger than the two
products ofwhich they are comprised.
There were also extra bands in PCR A-E which should distinguish splice form IV
from the others by using a primer in exon 1 which is specific for a sequence at the
beginning of this exon not seen in the other splice forms.
Here again, the larger unpredicted band appears to be a heteroduplex of the two other
products. The smaller unexplained product could represent a splice form that does
not retain intron 1 at all - giving a band of 178bp. There could be two possible causes
of this; either there was another undescribed splice form with the larger exon 1
similar splice form IV and a non-retained first intron, or splice form IV did not
actually have an extended exon 1 but rather all the splice forms had this, and so PCR
A-E produces the same result as PCR B-E in fact.
As mentioned in chapter 3 (see figure 3.2a) the sequences of splice forms types I-V
used to design the primers in this experiment are taken from individual clones.
Therefore the 5' end of these could be different from that described. This seems to be
the case when considering the results of PCR A-E i.e. exon 1 is longer than that seen
in splice forms I-III. Given this possibility, I have not considered the results of PCR
A-E to be indicative of the presence/absence of splice form IV.
Chapter 4 Characterisation of Clwd I: Expression ofmRNA and Protein 103
These results therefore, rather than distinguishing one splice form from another, were
really useful in distinguishing the different types of isoform from one another i.e.
there are Clwd splice forms that partially retain and fully retain intron 1 in their final
processed mRNA, and that there are splice forms that do and do not retain intron 2 in
the final processed mRNA. Splice form V could be distinguished from the others.
In addition to the primers described above I also subjected these samples to PCR
using a set of primers specific to Gapdh (Glyceraldehyde-3-phosphate
dehydrogenase). This is a gene that is strongly expressed, at all times and in all cells
as it is required for their basic metabolic function. As such it is known as a
"housekeeping gene" and so could be used as a constant against which the intensity
of the product produced by the various PCRs of the Clwd splice forms could be
measured.
As can be seen from the results of this experiment above, the intensity of the Gapdh
band is not constant when compared from tissue to tissue. This was expected as it is
extremely difficult to measure accurately the exact amount ofRNA that is subjected
to cDNA synthesis and there can be significant variation in the efficiency of reverse
transcription. As a result, I decided to make an approximate measure of the amount
of product produced by expressing it as a fraction of the Gapdh product produced. I
did this by using Scion Image software (Scion Corp) to measure the intensity of the
bands produced by PCR and expressing the products of the Clwd PCR as a fraction
of the Gapdh product intensity. As can be imagined this is a crude measurement of
the level of expression of the Clwd splice forms, but would allow me at least to get a
rough idea of relative abundance of the splice forms. Given the results of the RT-
PCR above, I believed the most informative way of looking at these results would be
to compare the abundance of the two products of the PCR B-E which would
represent the partially retained intron 1 (180bp) and the non-retained intron 1 (65bp),
and the two products ofPCR D-F which would represent the retained intron 2
(191bp) and the non-retained intron 2 (120bp).
A graph of the results is shown in figure 4.4
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Figure 4.4 Graph showing relative expression of each splice form of Clwd to that of Gapdh
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These results showed that there seems to be the following pattern of expression in
each of the tissues -partial retention of intron 1 < non-retention of intron 1, while for
intron 2 i.e. retention of intron 2« non-retention of intron 2, while there appears to
be strong expression of splice form V.
What must be borne in mind however, are the limitations of this particular method of
judging expression levels, in particular where two or more products are produced by
the same primer set. It can often be seen that when this is the case that the smaller
product is always more abundant than the larger as the reaction will preferentially
amplify the shorter product. It is worth noting however that the levels of splice forms
retaining intron 2 are greatly increased in the spleen. There does appear to be a
general increase in Clwd expression in the spleen, but specifically on comparing the
levels of splice forms retaining the second intron and not retaining it there seems to
be a far greater proportion of retained 2nd intron. This is especially noticeable when
looking at the retention of intron 1 in spleen, which seems hardly changed at all
compared to the other tissues.
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4.2.3 Matched tumour/normal expression array
In chapter 3 I described a database containing SAGE data from normal tissues and
tumours which, when queried with the Clwd tag sequence, suggested that Clwd
might exhibit increased expression in various cancers. In an attempt to corroborate
this with some in vitro evidence, I used a matched tumour/normal expression array
available from Clontech. This array consists of SMART™ -amplified cDNA from 68
tumour and corresponding normal tissues from individual patients spotted onto a
nylon membrane Clinical information for each individual sample can be seen in
section 2.A.3.
An IMAGE clone known to represent the human form ofClwd was used as a
template to produce a DIG-labelled Clwd cDNA probe by random primed labelling.
The array was then be incubated in a hybridisation solution containing the DIG-
labelled cDNA probe as described for a Northern blot in section 2.2.2.7 and 2.2.2.8.
The result can be seen in figure 4.5a with analysis in figure 4.5b.
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Number of patients showing
change in expression
Number of patients
showing no change in
expression
Kidney Yes 6 8
Breast Yes 1 8
Prostate Yes 1 2
Uterus Yes 2 5
Ovary No - -
Cervix Yes 0 1
Colon Yes 5 6
Lung Yes 0 3
Stomach No - -
Rectum No - -
| Small intestine | No - -
B
Cancer Metastasis? Patient age
and sex
Change
3 A/B Kidney renal cell carcinoma None seen 44yrs female Increased Clwd
in tumour
4 A/B Kidney renal cell carcinoma Metastasis to
bone
57yrs male Increased Clwd
in tumour
5 A/B Kidney renal oncocytoma Not available 73yrs male Increased Clwd
in tumour
9 A/B Kidney renal cell carcinoma None seen 50yrs female Decreased Clwd
in tumour
12 A/B Kidney renal cell carcinoma None seen 47yrs male Decreased Clwd
in tumour
13 A/B Kidney renal cell carcinoma None seen 56yrs male Decreased Clwd
in tumour




45yrs female Increased Clwd
in tumour
1 J/K Colon benign tumour Not available 81yrs male Decreased Clwd
in tumour
2 J/K Colon adenocarcinoma Metastasis to
liver
68yrs male Decreased Clwd
in tumour
3 J/K Colon adenocarcinoma NOS* None seen 64yrs male Decreased Clwd
in tumour
7 J/K Colon adenocarcinoma NOS* None seen 69yrs female Increased Clwd
in tumour
8 J/K Colon adenocarcinoma NOS* Metastasis to
lymph nodes
35yrs female Decreased Clwd
in tumour
*NOS - Not Otherwise Specified
Figure 4.5b Tables showing analysis of matched normal/tumour expression array data.
Table A summarises Clwd expression on the array i.e. the presence or absence of
Clwd and/or any change in Clwd expression on comparison of the normal and
tumour sample from each patient. Table B shows the in depth detail of the patients
for whom a change in Clwd expression was recorded. These changes were
estimated by eye from the appearance of the array as seen in figure 4.5a.
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Although it is difficult to say with certainty given the background, it is worth noting
that there appears to be little if any Clwd expression in the ovary, stomach and
rectum. At the very least there appears to be far higher expression elsewhere,
particularly the kidney, breast, prostate, uterus and colon. As for changes in Clwd
expression with the onset of a tumour, this seen in the kidney and colon tumours
primarily, with both increases and decreases noted.
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4.3 Expression of CLWD protein
4.3.1 Introduction
On looking at the splice forms produced by Clwd it is clear to see that there are
several categories of splice form, detectable by RT-PCR. To begin to explore the
function ofClwd, the next priority was to ascertain if there was a protein product
produced. I decided that the first step required to look at the Clwd protein would be
to make an anti-Clwd antibody.
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4.3.2 Design and production of an anti-peptide antibody against Clwd.
Anti-peptide antibodies had been prepared and used successfully against various
proteins by our group prior to my beginning this study. This, in addition to the fact
that their production is far less labour-intensive than the production of bacterially-
expressed proteins, was the main reason for choosing this method. The first step to
making this antibody was the design of a suitable peptide. To do this I had to take
several things into account. Firstly I wanted an antibody that would recognise both
human and mouse Clwd and so the peptide would have to come from a region where
there is a high degree of conservation between the two proteins. Secondly in order
for the peptide to be sufficiently antigenic i.e. for it to raise a good antibody response
in the sheep it would need to be in a region of the protein that would be exposed to
the immune system i.e. on the surface of the protein. Given these requirements I used
the programme PIX at HGMP to assess the antigenicity along the length of the








The amino acids underlined in the human and mouse Clwd sequences above are the
most antigenic portions of the protein i.e. they represent the regions that are most
hydrophilic and therefore most likely to lie on the surface of a correctly folded
protein. As can be seen here the first antigenic site in both human and mouse Clwd
are identical and so this was the peptide that I chose in order to raise an antibody.
This peptide was chemically synthesised with a cysteine added to the N-terminus to
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allow for the addition of keyhole limpet haemocyanin (KLH) which would increase
the immunogenicity of the peptide. The peptide was then used to immunise a sheep
as described in chapter 2 and I received a sample of pre-immune serum (taken from
the animal before immunisation) and three samples of post-immune serum taken at
one month intervals.
To begin to assess the efficiency with which this serum could act as an anti-Clwd
antibody, I first needed to prove that there were antibodies in the serum that would
recognise the peptide that was used to immunise the animal. I did this by carrying out
an ELISA (Enzyme-Linked Immunosorbent Assay). This ELISA involved linking
the peptide to wells of an immunosorbent plate, adding the serum and then an anti-
sheep secondary antibody that was conjugated to horseradish peroxidase. This
enzyme was then used to effect a colour change on a substrate (OPD - O-
PhenyleneDiamine) which would allow me to assess the function of any anti-Clwd
antibodies present in the serum.
The results of this ELISA are shown in the form of a graph of absorbance at 450nm
versus the logio of the concentration of the peptide (l-5000ng/ml) for the pre-
immune serum and the first two samples of post-immune serum. What can be seen is
that while the absorbance at various concentrations of pre-immune serum remained
at a low-level, with increasing peptide and serum concentration the absorbance of the
post-immune sera increased. Thus the post-immune serum was reacting to the
peptide and so did contain anti-Clwd antibodies.







































Figure 4.6 ELISA showing the positive reaction of the anti-peptide antibody to the peptide
representing Clwd
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4.3.3 Purification of antibody
The next step was to purify the post-immune serum in order to maximise the
concentration of these antibodies and minimise the presence of the various other
components of the sheep serum including other antibodies. As can be seen in figure
4.7, using the non-purified serum in a western blot of a human cell line resulted in a
large number of non-specific bands. The first step in purification was an ammonium
sulphate precipitation step to yield an immunoglobulin-enriched serum. This reduced
the number of bands seen on a western but further purification was required. This
was achieved by using an immunoaffinity purification step. I covalently attached the
peptide to a SulfoLink column and used this to extract and then elute that component
of the serum that would bind the peptide. This resulted in a single band when used on
a Western blot of a human neuroblastoma cell line (SH.SY 5Y). I had now purified
the serum to a form that could be used successfully on a Western blot.
It is important to note that this band albeit single and apparently specific was
approximately 28kD in size while, from the sequence of Clwd alone, the size of the
protein would be calculated at approximately 12kD. This would suggest that Clwd
was post-translationally modified which increased its size.
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Figure 4.7 Western blots detailing the increase in specificity of the anti-Clwd antibody
following rounds of purification. Arrowhead on each Western blot indicates the
position of the final strongly immunoreactive band as the serum is purified. Each
step in purification decreases the background level until only one band remains
in the final blot. This band is seen at 28kD rather than at 12kD as would be
expected for the Clwd protein. This may indicate post-translational modification
of Clwd takes place in vivo
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4.3.4 Expression in tissues
Having purified the serum so that it could be used as an anti-Clwd antibody, I then tested
a range ofmouse tissues to see where the Clwd protein was produced. The results are
shown in figure 4.8 below. What can be seen here is that Clwd does appear to have an
increased size compared to that which would be predicted from its amino acid sequence
alone. In addition some tissues, most notably spleen, but also liver, exhibited a doublet.
This could be due to a form of post-translational modification that is dynamic in nature
and so in a tissue one would find both the modified and non-modified forms - resulting
in a slightly different size of protein on a Western blot. An example of this kind of
modification would be phosphorylation or O-GlcNAcylation.
From this and other Western blots it became apparent that Clwd is as widely expressed









Figure 4.8 Western blot of mouse tissues using anti-Clwd antibody. Clwd expression could
be detected in all tissues examined. A doublet was observed in the liver and
spleen sample. This could be due to different phosphorylation states of the Clwd
protein in vivo
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4.4 Discussion
In this chapter I have described some of the first experiments I conducted on the
novel gene Clwd. Taking the information I had gleaned from the sequence of the
gene and open reading frame into consideration allowed me to design probes/primers
and a peptide/antibody to confirm the presence of Clwd as an expressed mRNA and
protein respectively in a wide range ofmouse tissues.
The RT-PCR results were very interesting. They confirmed some of the splice forms
that I had seen represented as ESTs and seemed to suggest that overall the balance of
splice forms is maintained from tissue to tissue. I also described some semi¬
quantitative analysis where I compared the intensity of the products produced by the
various PCR primers with that produced by Gapdh-specific PCR primers to get an
idea of the levels of Clwd seen in various tissues. Firstly, Clwd appeared to be
expressed to a similar degree in all the tissues examined, with particularly high
expression in the spleen. Secondly, of the types of splice form expressed it appeared
that those that do not retain the first and second intron are more highly expressed
than those that do. In the spleen however it also seemed that there was a larger
proportion ofClwd transcripts present with the second intron retained. This could
suggest a reduction in the level of Clwd's full ORF if this splice form acts as a
repressor as discussed in chapter 3.
It must be pointed out however that this analysis is a crude method ofobtaining
relative expression, as PCR is by no means a good way of quantitating expression.
Given these interesting suggestions though, and had I more time, the use of real time
PCR would be an excellent way of confirming these results.
Given the results obtained by SAGE, I also chose to look at total Clwd expression in
cancer as a preliminary examination of its role in tumourigenesis. By using the
matched normal/tumour expression array and a Clwd probe to hybridise it, it was
possible to determine the expression of Clwd cDNA in the tissues included on the
panel. In some of the tumours there were changes in Clwd expression. Both
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increased and decreased Clwd expression was noted with changes predominantly
seen in kidney and colon cancers. These included cancers that subsequently
metastasised and those where no metastasis was seen. It was impossible, therefore, to
draw any general conclusions from the results (e.g. in all colon cancers, Clwd is
increased). However, the changes in Clwd expression whether peculiar to the tissue
studied or to some tumourigenic state would be worth pursuing, particularly by
immunohistochemistry, even if that change represents a secondary effect of the
cancer on Clwd expression.
The antibody raised against Clwd appears to work well in that it identifies a single
specific band on a Western blot. This band is not of the size predicted by the amino
acid sequence, but could be accounted for by post-translational modification.
The experiments described here, allowed me to confidently say that Clwd was a gene
that produced mRNA and protein that appeared to be widely expressed as I had
predicted using various bioinformatic programmes. They had also provided me with
one of the most valuable tools with which I could further elucidate the function of
Clwd, an antibody.
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CHAPTER 5
CHARACTERISATION OF CLWD II:
LOCALISATION AND FUNCTION
5 Characterisation ofClwd II: Localisation and Function
5. Characterisation of Clwd II - Localisation and Function.
5.1 Introduction
Having confirmed that the novel gene Clwd is both transcribed and translated, the
next question to address was the role of Clwd in cells. To accomplish this it was
important to examine the subcellular localisation of the Clwd protein. If it was
possible to detect Clwd within the cell, ideally localised to a discrete organelle, this
would help in determining a potential function. The subcellular localisation
experiments were done by immunocytochemistry in two cell lines, the human
cervical carcinoma line, HeLa and the mouse embryonic fibroblast cell line,
NIH/3T3.
The establishment of the correct conditions for successful immunocytochemistry
would also be valuable for the next experiment to directly address Clwd's function
i.e., the use ofRNAi in cell culture in order to silence Clwd and ascertain the effect
this has on the cell.
RNAi or RNA interference is the term used to refer to the method of silencing genes
post-transcriptionally using double stranded or dsRNA. This form of gene silencing
had been used successfully as a powerful tool in the study of C. elegans genes for
some time before the method became tractable in mammalian cell culture. Studies
have shown that this method of gene silencing is mediated by the generation of small
interfering RNAs produced from the dsRNA molecules by the enzyme Dicer. These
siRNAs subsequently target the specific degradation of the mRNA to which they are
specific by an enzyme complex54.
The use of RNAi in mammalian cell culture was first described by Elbashir et al in
Nature53. It was discovered that while long stretches of dsRNA can function to
silence genes in C. elegans, these trigger an antiviral defence pathway in mammalian
cells involving the activation ofPKR, a kinase that phosphorylates EIF2a, which
responds by shutting down all translational activity54. siRNAs used to silence genes
in mammalian cell culture take the form of base-paired 21 nucleotide double
stranded RNAs with 3' overhanging ends. These siRNAs avoid triggering the
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activation ofPKR due to their small size and are presumed to be incorporated into
the RNAi pathway by mimicking the products of the Dicer enzyme, which catalyses
the initiation step of RNAi.
There has been some controversy regarding the specificity of these siRNA molecules
for their target.
One study in particular cast doubt on this specificity when they showed transcript
profiles which had siRNA-specific rather than target-specific signatures and the
direct silencing ofnon-targeted genes containing as few as eleven contiguous
nucleotides of identity to the siRNA56.
However there have been two further reports on the specificity of siRNAs. One study
used DNA microarrays to profile global gene expression upon the application of
siRNA to silence an exogenous gene. It was found there was no alteration in
expression of any gene other than the one for which the siRNA was specific . The
second report was more qualified in its conclusion. It stated that when strict rules
were applied to the design of the siRNAs, and the conditions for the transfection
were optimised, the technique can be highly specific, i.e. the global expression
signatures of different siRNAs against the same target correlate very closely, while
those for different genes do not. However if a high concentration of siRNA was used
(lOOnM) or there was some homology in the sequence designed and unwanted
CO
targets (>15nt in 21nt) then there can be non-specific silencing . Therefore the
recommendations of this and other papers were taken into consideration when
designing and carrying out the RNAi experiments. These will be described in section
5.3
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5.2 Subcellular localisation of Clwd
5.2.1 Fluorescent labelling of Clwd in cells
In order to assess where Clwd was expressed within the cell, several
immunocytochemistry experiments were conducted. The first experiment involved
testing if the anti-Clwd antibody could be used successfully in this type of protocol
and assessing the best method of fixing and permeabilising the cells to the antibody.
HeLa cells were grown on coverslips in 24-well plates for one to two days, until they
had adhered to the coverslip and were growing and dividing as normal. The cells
were then washed and fixed using a variety of methods. These included using ice-
cold methanol, an ice-cold 1:1 mix ofmethanol and acetone or 4%
paraformaldehyde. While methanol-based fixatives work by precipitating the
proteins in a cell such that diffuse protein may be lost, paraformaldehyde preserves
the native structure. With methanol-based fixatives, the cells are also permeabilised
by the treatment, but using paraformaldehyde means an extra permeabilisation step is
required. I used either triton X-100 or digitonin. Digitonin differs from triton in that
while it disrupts the plasmalemma, the intracellular membranes including the nuclear
envelope are left intact. Once fixed and permeabilised the cells were then incubated
with a blocking buffer containing Tween®-20 (a non-ionic detergent used for
disrupting unwanted lipid-protein interactions), BSA and serum from the animal in
which the secondary antibody was raised. In this case the secondary antibody for the
anti-Clwd primary antibody was a donkey anti-sheep antibody and so the serum used
was donkey serum. This blocking buffer prevented the non-specific adsorption of the
immunological reagents. The cells were then incubated in primary antibody and
secondary antibody, were counterstained with DAPI, a nuclear stain, and mounted on
a slide for viewing as described in chapter 2.
In this experiment the following negative controls were used. Firstly the cells were
treated with secondary antibody but not primary antibody to ensure that the
secondary antibody gave a signal only when it was bound to the primary antibody.
Secondly I preincubated the primary antibody with lng of the peptide against which
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it was raised. If the antibody was truly specific to Clwd and indicated Clwd's
presence in a cell, then the addition of the peptide should reduce this signal by
blocking those sites on the anti-Clwd antibody that would recognise Clwd.
As can be seen in figure 5.1 it appears that the methanol/acetone method of fixation
minimised the signal in the negative controls while maximising that of the positive
control and so this was the method used for future experiments. On examining the
staining of the cells it appears that the antibody stains the cytoplasm with the
strongest signal around the nucleus. The lower panels show the MeOH-acetone fixed
HeLa cells with the DAPI counterstain highlighting the staining around the nucleus.
Given that there is also staining in the cytoplasm, it is less likely that Clwd was an
integral part of the nuclear membrane itself, but rather that its expression while
generally cytoplasmic, is concentrated at the interface between the nucleus and the
cytoplasm perhaps to perform a particular function.
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Anti-Clwd Ab Anti-Clwd Ab with DAPI
Figure 5.1 Anti-Clwd antibody staining of HeLa cells fixed by a variety of methods
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5.2.2 Co-localisation with oraanelle markers
w
Following the initial immunofluorescence experiment results, I conducted several
double-labelling experiments to determine if Clwd co-localised with a known
protein, of specific expression pattern. These experiments were conducted in
NIH/3T3 cells, a mouse fibroblast cell line, rather than the human cell line HeLa
used in the previous experiments. I first used an organelle sampler kit (BD
Transduction Laboratories) that contained antibodies against a variety of proteins
that were markers of particular organelles. These antibodies and their associated







While these antibodies were raised in mice, the anti Clwd antibody was raised in
sheep. This meant that if the anti-mouse antibody and anti-sheep antibody were
labelled with different fluorescent probes, both Clwd and the marker of interest could
be detected in the same set of cells and the two images merged to determine if they
were co-localised. The organelle markers were stained green, Clwd stained red and
where these two colours are co-localised in the merged picture the staining appears
yellow. The most promising marker, in terms of co-localisation with Clwd is
Paxillin, as seen in figure 5.2.
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Figure 5.2 Double labelling of NIH/3T3 cells with Clwd antibody and various organelle
markers
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While the staining ofGM130, Caveolin and Paxillin appear specific the cells stained
with the anti-annexin II antibody and the p-catenin appear to have a far broader
expression pattern than one would expect from antibodies staining the plasmalemma
and zonula adherens. While the panels in figure 5.2 show cells stained for both the
organelle marker and Clwd at the same time, cells stained for the organelle marker
alone gave a different staining pattern, as can be seen in figure 5.3. It may be that
there is some cross reaction between these particular antibodies and the Clwd
antibody. Either way, neither expression pattern is similar to Clwd.
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Double-stained cells viewed with FITC filter Single-stained cells
Figure 5.3 NIH/3T3 cells stained with anti-Annexin II antibody and anti-(3-Catenin antibody
alone or in conjunction with anti-Clwd antibody
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The next figures are the results of co-localisation experiments firstly with additional
Golgi apparatus markers (figures 5.4 and 5.5) and secondly with markers of the
nuclear envelope such as Lamin A/C (figures 5.6 and 5.8) and Nuclear pore O-linked
glycoprotein (figure 5.7). With Clwd expression mainly in the cytoplasm but
concentrated at the nuclear envelope both the Golgi apparatus and the components of
the nuclear envelopes were good candidates for the position of Clwd. These
experiments were carried out in both HeLa and NIH/3T3 cell lines as noted in the
figures.
The Golgi apparatus is a collection of flattened membranes, or cistemae, and
vesicles. Proteins mature and are modified after their biosynthesis at the ER and
transported through the Golgi apparatus. This involves the transport of protein-
containing vesicles through a process of vesicle budding and fusion from the cis-
compartment (CGN) to the medial-compartment (MGN) and the trans-compartment
(TGN) of the Golgi apparatus.
While the Golgi marker GM130 did not co-localise well with Clwd (figure 5.2),
given its location within the cis-Golgi compartment and the fact that the Golgi is a
large organelle, I felt it was important to examine other components. In this
experiment, I examined the localisation ofVtila (figure 5.4) and Vtilb (figure 5.5).
Both these proteins are involved in vesicle transport, with Ytila functioning in
protein transport within the secretory pathway and Vtilb involved in the regulation
of post-Golgi vesicle trafficking. As these proteins are found in trafficking vesicles,
it is possible that they have a more diffuse pattern of expression than GM130 and so
would be better candidates to be co-localised with Clwd





































































In NIH/3T3 cells Vtila and particularly Vtilb expression is seen in the cytoplasm
more than restricted to the cis-Golgi as GM130 was, and so is closer to the pattern of
Clwd expression. However in HeLa cells Vtila and b expression is more similar to
that ofGM130 and found to one side of the nucleus. Clwd expression, in contrast,
surrounds the nucleus. It seems unlikely therefore that Clwd is part of the Golgi
apparatus
Given the staining pattern ofClwd seen surrounding the nucleus, markers of the
nuclear envelope were the next tested. The markers chosen here were Lamin AJC and
Nuclear pore O-linked glycoprotein. Lamin AJC is a type V nuclear lamin. The
lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic
side of the inner nuclear membrane which is suggested to provide a framework for
the nuclear envelope and may interact with chromatin.
Nuclear pore O-linked glycoprotein antibody actually detects up to eight different
proteins from the nuclear pore complex (NPC). The NPC spans the dual membrane
of the nuclear envelope and acts as a gateway for macromolecular traffic between the
cytoplasm and the nucleus.
In these panels, Lamin A/C and Nuclear pore O-linked glycoprotein appear green,
Clwd is red and where these co-localise is yellow.
The results of the double labelling can be seen in Figure 5.6, 5.7 and 5.8.
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Cellsstainedwithan i-LaminA/Ctibo yalon
Figure5.8NIH/3T3cellsstainedwithClwdanLamA/C. Chapter5CharacterisationoflwdII:Loc lis tionndFunction
In this co-localisation experiment, in both cell lines and antibodies, there appears to
be some cross-reaction between the antibodies. The expression pattern ofClwd in the
HeLa cells stained with anti-Clwd and anti-Lamin A/C antibodies (figure 5.6) is
completely different from that seen previously as there is Clwd-staining in the
nucleus. In addition the Lamin A/C staining differs depending on whether or not
Clwd is present. In the NIH/3T3 experiment (figure 5.8) however, LaminA/C
appears to have a completely different expression pattern, one very similar to that of
Clwd. As the expression pattern in the cells stained with anti-Lamin A/C alone is
similar to that in the double labelling experiment, it does not appear that the cross-
reaction seen in HeLa cells is relevant here. Why this should be so is unclear.
In the nuclear pore co-localisation (figure 5.7), the expression pattern of the proteins
recognised by the anti-Nuclear pore O-linked glycoprotein antibody is again quite
similar to Clwd although it is possible, in the merged image panels, to see that Clwd
is found in the cytoplasm around the borders of the nucleus whereas the nuclear pore
complex proteins are not.
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5.3 Gene silencing by RNAi
5.3.1 Design of siRNA
Strict rules need to be applied to the design of the siRNAs to ensure that they are
both efficient and specific for the gene in question. The rules I adopted were those
described by the Tuschl lab at their website "The siRNA User Guide" which can be
found at http://www.rockefeller.edu/labheads/tuschl/sirna.html. These state that the
target sequence of the gene in question should begin 50 to 100 nucleotides
downstream of the start codon, and the sequence used should have the structure
AA(N19)TT where N is any nucleotide. The target sequence should have
approximately 50% G/C content and this sequence should be unique to the gene of
interest to eliminate cross-reactivity.
The siRNAs chosen for Clwd were Clwd+89 aagtgccgagtaccctgggga and
Clwd+183 aaatccacactcccgttcatg (see figure 5.9) which were 89 and 183
nucleotides from the start codon respectively. While there were no suitable
AA(N19)TT sites, I used the next option recommended AA(N21). Clwd+89had 68%
GC content and Clwd+I83, 52% GC content. Using BLAST to compare these to other
mouse cDNA sequences it was found that both were specific for Clwd. Having
designed these target sequences the sense and antisense siRNA sequences were
ordered from Xeragon along with a negative control siRNA available from the
Xeragon library.
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Clwcf89:
Target sequence 5'-aagtgccgagtaccctgggga-3'
Sense siRNA: 5'-r (gugccgaguacccugggga) dTT-3'
Antisense siRNA 5'-r (uccccaggguacacggcac) dTT-3'
Clwd+183:
Target sequence: 5'-aaatccacactcccgttcatg-3'
Sense siRNA: 5'-r (auccacacucccguucaug) dTT-3'








-1 0 +1 +2 +3 +4 +5
Figure 5.9 Diagrams showing the siRNAs used to silence Clwd, and the timeline of an RNAi
experiment.
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5.3.2 Knock-down of Clwd expression using RNAi
Upon receipt of the siRNAs, the sense and antisense strands were annealed and
transfected into NIH/3T3 cells as described in chapter 2. The cells were plated on
day -1 in 24-well plates and transfected on day 0 with samples taken from day 2 to
day 5 as shown in figure 5.9. The NIH/3T3 samples taken on these days belonged to
5 different treatment groups as described below:
No treatment:
Cells were not transfected at all and once plated remained untouched until samples
were taken on the indicated days.
Mock transfection:
These were cells that were subjected to Oligofectamine™ and OptiMEM® as for the
transfected cells, except with no siRNA present. This control served to judge the
effect the transfection procedure had on the cells.
Control siRNA:
These cells were transfected with the control siRNA. This would show the effect of
random siRNA molecules, with no specificity for any gene, on the cell.
Clwd"1"89 siRNA/Clwd+183 siRNA:
This was the transfection of the siRNAs specific for Clwd as described earlier. Any
phenotype seen in these cells and not in the control cells would be deemed a result of
the knock-down ofClwd expression.
In the first RNAi experiment the efficiency of the Clwd siRNAs was tested. This was
done by extracting the protein from the transfected cells, 2-5 days post-transfection
and using the anti-Clwd antibody to assess Clwd expression on a Western blot of
these extracts. a-Tubulin was the loading control for the Western blot, and (as for
the RT-PCR experiment in chapter 4) Scion Image software expressed the level of
Clwd expression in relation to the level of a-Tubulin expression. The results of this
experiment are shown in figure 5.10.
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Figure 5.10 Western blot of the protein extracted from cells transfected with siRNA and
histogram describing Clwd expression in these extracts. In this experiment,
Clwd expression in reduced in the Clwd+89and Clwd+183 samples on days 3
and 4 in comparison to the negative controls while on day 5 the expression of
Clwd appears to have recovered.
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The graph in figure 5.10 shows the relative expression ofClwd to a-Tubulin on
sample days 3 to 5 (given that the expression of both Clwd and a-Tubulin is
extremely low on day 2 this is not shown in the graph). The first thing to notice is
• • j_OQ 4-1RT
that it appears that Clwd expression is reduced in the Clwd and Clwd samples
on days 3 and 4 in comparison to the negative controls, while on day 5 it appears that
expression has recovered. However it is worth noting that it appears that Clwd
expression is reduced in the control siRNA-treated samples also. Although this
reduction is never as great as that in the Clwd siRNA-treated samples it is important
as the sequence of the control bears no relation to Clwd (or any other mouse RNA
sequence) and so how it can apparently reduce Clwd expression is unclear. One
explanation could be that the transfection of siRNA is having some broad general
effect on the state of the cell and as a result is having a secondary effect on Clwd.
This control siRNA has been used by other groups successfully however and so does
not seem to be a general feature of this particular sequence of siRNA. Nevertheless
in my hands the transfection of siRNA appears to have some effect on the cells in
addition to the effect of a mock transfection.
Despite this anomaly there is a further reduction ofClwd expression in both Clwd
siRNA-treated samples, and the fact that the transfection of two different siRNA
sequences targeting the same gene result in a decrease in Clwd expression in
comparison to the control siRNA is highly significant in attempting to assess the
validity of the RNAi experiment.
Following this result, it was important to determine the phenotype associated with
this reduction in Clwd expression. To accomplish this, the cells were plated on
coverslips in 24-well plates in order that the cells could be stained by the anti-Clwd
antibody and visualise the Clwd-silenced cells by immunofluorescence. The results
of this experiment can be seen in figure 5.11.
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Day 1 : Clwd Day 3 : Clwd Day 3 : Clwd and nucleus stain
Day 3 : Control siRNA Day 3 : Clwd+BM siRNA Day 3 : Clwd+1B3 siRNA
Figure 5.11 Clwd silencing in NIH/3T3 cells. Lower panels compare nuclei from
negative control siRNA transfected cells and anti-Clwd siRNA transfected cells.
Arrows highlight apparent vacuoles and protrusions.
Chapter 5 Characterisation ofClwd II: Localisation and Function 143
The advantage to viewing the immunofluorescence image of an RNAi experiment is
that it is possible to examine on a cell by cell basis if the gene expression has been
reduced and the effect, if any, on that cell. This is an improvement on determining
the overall expression on a population of cells as not all cells are necessarily
transfected and even a cursory evaluation of phenotype is impossible.
• • "bRQ
As can be seen from the immunofluorescence results seen in figure 5.11, Clwd
decreases Clwd expression in the cell. It should be noted that all of the images above
were taken with the same fixed exposure so that the intensity of the staining could be
directly compared. The amount of Clwd expression did not seem to be as decreased
in the Clwd+183. There was a phenotype associated with the loss of Clwd. There were
far fewer cells in the wells treated with both the Clwd siRNAs than in the controls.
The nuclei of the Clwd siRNA-treated cells were irregular in shape with protrusions
and vacuole-like gaps in DAPI staining - this was not seen in the control siRNA-
treated cells. These aspects of the Clwd siRNA treated cells were seen as early as one
day post-transfection and were still visible at 2 days later.
It seemed therefore that the loss of Clwd was having an effect upon either the growth
or survival of the cells and upon the structure of the nucleus
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5.3.3 Problems with RNAi
Unfortunately, in the remaining time since these experiments were carried out, I have
been unable to reproduce Clwd silencing using siRNA. I addressed the possible
reasons for this in a variety ofways.
In an attempt to address the potential problem of transfection efficiency, NIH/3T3
cells were ordered from ECACC. These would be of low passage number and
guaranteed mycoplasma-free, two important factors in maintaining efficient and
consistent transfection. I maintained this cell line in the recommended medium
without antibiotics and without allowing it to reach confluency. In addition, a
positive control siRNA was ordered from Qiagen that had been proven to be efficient
in silencing Vinculin expression in NIH/3T3 cells. Using these fresh, low passage
number cells and the positive control siRNA I tested a variety of siRNA transfection
reagents described in RNAi experiments and the effect of the initial cell density on
the success of the experiment. The results can be seen in figure 5.12. It can be seen
that the best transfection reagent appears to be RNAiFect™ (Qiagen). This delivered
the siRNA which reduced Vinculin expression by half in all bar one of the days that
samples were taken. Using this agent and the recommended protocol from the
manufacturer, an RNAi experiment to silence Vinculin and Clwd was carried out and
the cells analysed by immunofluorescence, but unfortunately neither siRNA achieved
silencing. Whether this was an intermittent transfection problem, or the siRNAs
being used were contaminated or had deteriorated in some way is unknown, and
unfortunately time did not permit me to carry out further experiments.
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Figure 5.12 Efficiency of transfection reagents in delivering Vincuiin siRNA - RNAi positive
control.
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5.4 Discussion
In this chapter I have described the steps I took to gain more information about the
role Clwd might play in the cell. To do this I used two techniques,
immunofluorescence to determine subcellular localisation and gene silencing in cell
lines by RNAi
5.4.1 Subcellular Localisation
Using the anti-Clwd antibody described in chapter 4 and a secondary antibody with a
fluorescent tag, it was possible to visualise Clwd in cell lines and make an
assessment as to its location in the cell. In both NIH/3T3 cells and HeLa cells Clwd
appears to be located in the cytoplasm with more concentrated staining surrounding
the nucleus. Using an organelle marker system of antibodies Clwd appeared to have
an expression pattern in the cells most similar to that ofPaxillin.
Paxillin is a multi-domain protein that localises primarily to sites of cell adhesion to
the extracellular matrix called focal adhesions in cultured cells. These focal
adhesions form a structural link between the extracellular matrix and the actin
cytoskeleton and are also important sites of signal transduction as Paxillin, like other
focal adhesion proteins, serve as a point of convergence for signals resulting from
stimulation of various classes of growth factor receptor.
This co-localisation of Clwd with Paxillin could suggest therefore that Clwd is either
one of the other structural proteins, similar to Paxillin at the focal adhesions of the
cell, or is it one of the signalling molecules taking part in a pathway situated at the
site of Paxillin.
Given Clwd's small size, potential for phosphorylation/O-GlcNAcylation and lack of
any known structural domains, I would suggest it is more likely to be a small
undescribed signalling molecule, perhaps activated and inactivated by
phosphorylation rather than a structural protein.
The co-localisation experiments with the Golgi markers and nuclear envelope
markers were not as clear-cut. In some examples it appeared that each antibody,
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when used to stain cells simultaneously, influenced the staining of the other. The
reason for this is unclear, other than there is a form cross-reaction taking place with
the secondary antibodies recognising both primaries even though they have
supposedly different specificities.
5.4.2 RNAi
In this chapter I also described the use ofRNAi in order to assess the effect on a cell
once Clwd expression has been silenced. A decrease in Clwd expression was
detected by Western blot and upon staining the cells by immunofluorescence. This
confirmed that the siRNA designed had worked well. It also provided further
evidence that the anti-Clwd antibody produced was specific for Clwd as transfecting
Clwd-specific siRNA molecules resulted in a decreased signal from the antibody.
The immunofluorescence experiment allowed an initial assessment of the cell
phenotype resulting from reduced Clwd expression. Upon examination of the Clwd-
silenced cells, there were far fewer cells than in the negative control siRNA-
transfected cells. This could imply that there was a decrease in growth or survival of
the cells. In addition the morphology of the DAPI-stained nucleus appeared unusual
in those cells transfected by the anti-Clwd siRNA. There appeared to be gaps in the
staining such that the nuclei seemed to exhibit vacuoles. There were also protrusions
ofDAPI-stain extending from the usually tightly formed oval structure of the nucleus
as seen in the control siRNA-transfected cells
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CHAPTER 6
IMMUNE SYSTEM PHENOTYPE OF WASTED MICE
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6. Immune System Phenotype of Wasted Mice
6.1 Introduction
In this chapter I will describe a preliminary investigation into the cause of the
immune system defects seen in wasted mice as described in chapter 1. Clwd was
examined initially as it was situated close to the wasted deletion and so could play a
role in the pathology of wasted mice. In particular, as there appeared to be no role for
eEFlA2 in the immune system, it was thought that the abnormalities here could be
attributable to Clwd.
I will introduce the results of experiments examining this hypothesis with the work
ofDawn Loh who created the transgenic animals I used to assess the role of Clwd in
the wasted mice. This transgenic experiment was designed in the first instance to
rescue wasted mice by supplying an intact copy of the genomic region surrounding
the wasted deletion. The construct used was a genomic BAC clone (RPCI-22-219F24
referred to as 219F24) that carried: the first exon of a voltage-gated potassium
channel gene Kcnq2, Eefla2, Clwd and the protein tyrosine kinase gene Ptk6 but
without its 5' UTR and promoter sequences. It was hoped that this would replace the
lost functionality of the wasted deletion and thus rescue the wasted mice. To test
what portion of the wasted pathology was attributable to the loss ofEefla2, the same
genomic BAC clone was engineered to have a deletion within Eefla2 removing
exons 2-4 and thus the start codon for the protein and all three GTP-binding domains
essential for eEFlA2 function (referred to as del219F24). IfeEFlA2 was solely
responsible for the wasted pathology then while the intact BAC, 219F24, would
rescue the wasted mice, the BAC with a portion ofEefla2 deleted, del219F24, would
not. However if Clwd were partially responsible for the wasted phenotype then
wasted mice carrying del219F24 would have a partially corrected phenotype e.g. if
Clwd were responsible for the immune system abnormalities, it could be expected
that these mice would still develop muscle wasting and tremors, but their spleen and
thymus would be as normal. See figure 6.1 for a diagram of these constructs.
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In order to genotype animals carrying these transgenes a system ofPCR primers was
used that could distinguish the wild type allele (P2) at the wasted locus, the wasted
allele (wstspan) and the presence of the BAC constructs (B1162-3).
While the wild type allele primers were designed to amplify a portion of the wasted
deletion sequence, the wasted allele primers consisted of a split forward primer
(wstspan-f) and a reverse primer (wstspan-r). The split primer was designed with 18
nucleotides from just outside the 5'end of the wasted deletion and six nucleotides
from just outside the 3' end of the wasted deletion. The regular primer was designed
from exon 2 ofEefla2. A positive result for this PCR would mean that the split
primer would no longer be split due to the loss of the intervening wasted deletion

















Figure 6.2 Diagram showing the primers for the genotyping PCRs
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However this presented a problem as a genotyping strategy. As 219F24 was a
genomic clone, it also represented a wild type allele as denoted by a positive P2 PCR
result. Therefore, by PCR genotyping alone it could not be determined if a particular
mouse positive for all three PCRs was an unaffected heterozygote carrying a
transgene or a wasted homozygote rescued by the carried transgene. This is best
explained in the table below.
wstspan P2 B1162-3 Genotype
- + - Wild type, non-transgenic
- + + Wild type transgenic
+ + - Wasted heterozygote, non-transgenic
+ - - Wasted homozygote, non-transgenic
+ + + Wasted heterozygote, transgenic
OR
Wasted homozygote, transgenic
This meant that whether 219F24 and/or del219F24 rescued the wasted mice or not
had to be determined by counting the number ofwasted mice that were produced
from crosses ofwasted heterozygote mice, with one parent carrying the transgene.
The normal frequency of a wasted mouse produced from a heterozygote cross would
be one in four. This frequency would remain the same if the transgene did not rescue
the wasted phenotype. However, if the transgene did rescue the phenotype, the
number ofwasted mice produced should be reduced to at least one in eight (given a
copy number of one). The frequency ofwasted homozygotes produced will remain at
1 in 4 but at least half of these homozygotes will carry a transgene and so while
homozygous, will not result in a wasted mouse (see figure 6.3)
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6.2 Is Clwd a good candidate?
6.2.1 Transgenic experiment to correct wasted phenotype
There were 4 transmitting founder mice for the 219F24 (A261, A262, A262.1,
A262.2) and 1 transmitting founder for the del219F24 (A240). I established a
breeding programme for each of these lines such that each line had at least one
breeding pair with one parent carrying the transgene, and both heterozygous for the
wasted allele.
The offspring from these matings were genotyped and monitored for the number of
phenotypically wasted mice. Using binomial distribution it was possible to calculate
the probability that the observed number of wasted mice produced showed the
possible frequencies of 1 in 4 (0.25) or 1 in 8 (0.125). These data can be seen below.
del219F24
Line Wasted Offspring Total Offspring P value at 0.25 P value at
0.125
A240 19 88 0.27 0.01
219F24
Line Wasted Offspring Total Offspring P value at 0.25 P value at
0.125
A261 3 34 0.02 0.37
A262 6 40 0.1 0.38
A262.1 1 9 0.3 0.69
A262.2 2 21 0.07 0.5
Total 12 104 0.0003 0.12
What can be seen here is that in the case of the del219F24 line A240, the numbers
observed were more likely to be at a frequency of 0.25 than 0.125, while in the case
of each of the 219F24 lines the observed numbers ofwasted mice were more likely
to occur at a frequency of 0.125 than 0.25.
It appears therefore that the presence of 219F24 in a homozygous wasted mouse is
enough to rescue that mouse from phenotype. It should also be noted that no wasted
mouse produced in these crosses was transgenic.
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However the presence of del219F24 was not enough to rescue the wasted mice. Here
there were several obviously wasted mice that were transgene positive and upon
examination it was found that these animals exhibited the spleen and thymus atrophy
apparent in non-transgenic wasted mice. It therefore seemed that the loss of
functional eEFlA2 was solely responsible for the whole of the wasted phenotype.
It was important in these animals, however to ensure that this transgene was actually
being expressed, as there was no difference between transgenic positive and negative
mice. To do this a Western blot was carried out which compared the level of Clwd
expression in transgenic and non-transgenic animals. As the transgene contained an
intact copy of Clwd, if it was expressed, then there should at least be a 1.5-fold
increase in Clwd expression in the transgenic animals given a copy-number of one.
Using kidney protein extracts from both transgenic and non-transgenic animals, a
Western blot was carried out using the anti-Clwd antibody and anti-a-Tubulin as a
loading control. Kidney extracts were used as this tissue has never been implicated in
any of the disease processes associated with wasted mice. The results can be seen in
figure 6.4 in addition to graphs comparing the ratio ofClwd to a-Tubulin expression
in each of the tissues examined. Using an unpaired t-test to examine how different
these two sets of data are, it was found that the two-tailed P value equalled 0.0175
which, by conventional criteria, was a difference considered to be statistically
significant. Looking at the average values for the mice examined it appears that Clwd
expression in transgenic mice is approximately 1.5 times that of the non-transgenic
mice and so suggests a copy-number of 1.
This implies that the transgene, although expressing Clwd, cannot rescue any aspect
of the wasted phenotype and so that Clwd is not responsible for the pathology of
wasted mice.















































Figure 6.4 Comparison of Clwd expression in kidney protein extracts from wild type (N1-4)
and transgenic (TG1-4) mice from the A240 line of del219F24.
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6.2.2 Comparison of Clwd expression in wild type and wasted mice
Having an anti-Clwd antibody was extremely useful to compare the expression ofClwd
in wild type and wasted mice. Western blots using this antibody showed that, for all the
tissues examined, there did not appear to be any difference in expression of Clwd
between wst/wst and wild type mice. The only difference at all appeared in the spleen
where the wild type spleen exhibited a doublet whereas only a singlet was apparent in
the wasted lane. Although there was evidence of alternative splice forms ofClwd, these
are predicted to produce either full-length protein or one so truncated (20 amino acids
long) that it is unlikely to be produced in vivo. I have speculated previously (see chapter
4) that this doublet is present due to alternatively phosphorylated forms ofClwd. If this
is true it is unlikely that this is a major difference then between wild type and wasted
spleen as phosphorylation is often a transient change to a protein and so is more likely to
be relevant to the state of the tissue when it was acquired than any real major change in
the expression ofClwd.
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Figure 6.5 Clwd expression in wild type and wasted tissues. Using the anti-Clwd antibody on
a Western blot there appears to be no difference in the expression of Clwd
between wild type and wasted tissues. In the spleen a doublet is apparent in the
wild type sample which is not seen in the wasted sample. This could be due to
differences in the phosphorylation status of Clwd between the two tissues
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6.3 Is eEF1A2 a good candidate? Expression in dendritic cells.
It now seemed that eEFlA2 was a better candidate for the immune system pathology
of wasted mice than Clwd. As discussed in the introduction to this thesis, there was
some evidence in the literature that eEFlA2 might be expressed in the dendritic cells
of the immune system - even though this expression was not detectable in a whole
immune system organ such as the spleen or thymus. In addition to this paper, an
article describing Prof. ColinWatts' work at the University ofDundee drew our
attention to the microarray data collected by his group examining the differences in
expression profile between immature and mature dendritic cells59. Following
personal communications with ProfWatts, it was discovered that according to these
microarray data, Eeflal expression decreased approximately 10-fold upon
maturation of dendritic cells. As an apparent isoform-switch takes place in wild type
muscle (i.e. upon the decrease in eEFl A1 post-natally eEFlA2 expression increases)
it was possible that something similar was occurring upon the maturation of dendritic
cells. To address this possibility the expression levels ofEeflal and Eefla2 were
monitored by RT-PCR on bone marrow-derived dendritic cell mRNA kindly donated
by Prof. Watts. The mRNA came from dendritic cells before and after the LPS
(LipoPolySaccharide) treatment that induces maturation. In addition to Eeflal and
Eefla2 the levels of three different maturation markers were also examined - Fnl
(Fibronectin 1), Ccl5 (Chemokine (C-C motif) ligand 5 ) and IIlb (Interleukin 1
beta). On maturation of dendritic cells, expression ofFnl decreases while that of
Ccl5 and Illb increases. Figure 6.5 shows the RT-PCR experiment examining the
expression of these genes. As can be seen from this result, the maturation markers
behave as expected. Both Eeflal and Eefla2 are expressed in dendritic cells with
Eeflal expression dramatically decreasing on maturation while Eefla2 expression
increases slightly.
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Figure 6.6 Eef1a1, Eef1a2 and maturation marker expression by RT-PCR in dendritic cells
with and without LPS treatment
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6.4 Discussion.
Following the comparison of Clwd expression in wild type and wasted mice and in
particular the transgenic experiment described here, it became apparent that the
likelihood of the wasted deletion having a functional impact on Clwd was slim.
The transgenic experiment also suggested it was only the wasted deletion's effect
upon Eefla2 that resulted in the total pathology associated with the wasted mice.
As this became apparent, a preliminary investigation into the expression ofEefla2 in
the dendritic cells of the immune system was conducted and it was found that Eefla2
was indeed expressed in the dendritic cells. It was also discovered that on maturation
of the dendritic cell there was a sharp decrease in Eeflal expression. This could
mean that in mature dendritic cells eEFlA2 is of increased importance. How a loss of
eEFlA2 expression, as in wasted mice, would affect the dendritic cell population is
unclear and how this affected population of cells could cause the immune system
abnormalities observed in wasted mice is unknown. This work does serve to prove
however that not only is Eefla2 expressed in a component of the immune system, but
also it appears its expression is vital not only to that component but the whole
system. Perhaps in future a conditional knockout ofEefla2 in the immune system
would allow its role in this system to be assessed in more detail






7.1 Aims and Methodology
The aim of this project was to test if a novel gene discovered in the vicinity of the
wasted deletion was involved in the immune system abnormalities observed in the
mouse mutant wasted. Having determined at the start of this project that this novel
gene was a good candidate to study, I decided first to characterise this gene and its
protein product before addressing its potential role in the pathology of the wasted
immune system. I planned to do this by conducting an as detailed as possible
examination of the novel gene Clwd in silico in order to inform my future in vitro
work. Subsequently I hoped to use this information to confirm that this gene,
predicted by various gene prediction programmes did produce an mRNA transcript
and protein product. Finally I planned to use the information collated thus far to
elucidate the function of the protein product of this gene.
Having completed this characterisation of the gene, I hoped to address whether or not
it played a role in the wasted phenotype. This would be done by examining the
results of a transgenic experiment in addition to using my new knowledge of Clwd
and its features to assess the part it played, if any in this pathology.
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7.2 The novel gene Clwd in silico and in vitro
Clwd was initially uncovered by my group through the careful cloning and
sequencing associated with mapping a genetic lesion resulting from a classical
mutation. In this case the lesion was the wasted deletion which removes 15.8kb of
distal mouse chromosome 2. It was seen originally as a portion of the sequence with
an apparent CpG island and homology to a large number ofESTs.
Two advances during the course of the project made the study of Clwd as a novel
gene easier. Firstly the mouse genome was in the process of, and then finally
sequenced50 and with this came an emphasis on gene prediction programmes to
annotate new genes by learning from the structure ofknown genes. Secondly the
sequence of the mouse transcriptome became available with the advent of full-length
mouse cDNA clones60. These two advances made my study of Clwd as a predicted
gene far easier and allowed me to use the wealth ofnew software online to predict its
potential structure and function. From these I had confirmed Clwd genome and
mRNA sequence which I used to elucidate the intron-exon structure of the gene.
From the alignment of these sequences I could determine that Clwd appeared to be
alternatively spliced. This alternative splicing took the form of skipped exons as in
the majority of alternative splicing events, but also a combination of the use of
alternative 5'and 3' donor sites in the first and second exons, and the retention of the
first and second introns, the latter being relatively rare in known alternatively spliced
genes. There were 5 splice forms in all.
Most of the alternatively splice locations occurred in the 5'UTR. This is not unusual
as can be seen in figure 7.1. It is thought that alternative splicing in the 5'UTR can
lead to alterations in the stability and/or localisation of the mature mRNA without
changing the sequence of the protein. However the splice location ofmajor interest,
that could really affect the production of a functional Clwd protein, was that which
occurred within the coding sequence i.e. the retention of the second intron.
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Due to the retention of intron 2 in splice form II, IV and V, a premature stop codon
would be predicted to occur in the transcript from this intronic sequence. If true, this
would have several implications. In most cases if a termination codon appears more
than 50 nucleotides upstream of the final exon it is a PTC (Premature Termination
Codon) and the mRNA that harbours it will be degraded by nonsense-mediated
decay (NMD)61. This is a form ofRNA quality control which prevents the translation
of potentially dominant negative, C-terminal truncated proteins. This type of
regulated splicing to produce unproductive isoforms is also used as a means of down
regulating protein expression, as these mRNA isoforms remain untranslated. In C.
elegans for example, the expression of the ribosomal proteins L3, L7a, LlOa and L12
are regulated post-transcriptionally via the coupling of alternative splicing and
NMD62.
Alternative Splice Location






Alternative 3' splice site □
Alternative 5' splice site D
Figure 7.1 Pie charts depicting prevalence of various forms of alternative splicing in a
random sample of alternatively spliced genes in human (from ref63)
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Looking at the expression of the splice forms mouse tissues by RT-PCR it appeared
that the splice forms representing the retention of intron 2 were the least represented
in each of the tissue examined. The other type of splice form, i.e. where the splice
occurred in the 5'UTR, were more highly expressed. This would seem to suggest
again that while changes to the 5'UTR can affect the transcript, it is the presence of a
PTC that would have a more devastating effect.
It is worth noting however that the proportion ofClwd mRNA retaining this second
intron is dramatically increased in the spleen sample examined. Why this occurs is
unclear. Is it that in the spleen there is increased production of the forms retaining
intron 2, or rather that these forms survive NMD by some mechanism? There has
been some recent evidence that NMD can be tissue-specific in nature. Specifically, a
Schmid metaphyseal chondrodysplasia patient with amutation in the gene for
collagen X resulted in a transcript with a PTC. This led to complete NMD of the
transcript and thus collagen X haploinsufficiency in the cartilage of this patient.
However the mutant mRNA has been found in non-cartilage cells - lymphoblasts
and bone cells - and is not subject to NMD64. This would suggest that RNA
surveillance and NMD can be regulated in some way and so the presence of a PTC in
a transcript does not necessarily mean that transcript is degraded by NMD.
From my results there appeared to be a variety of splice variants present in each
tissue. It is worth noting however that these images are just snapshots of the tissue at
the time of retrieval. Clwd may exert its effect on a more cellular level such that in
some cell types form I is more prevalent, where in others form V is the dominant
form for example. Another possibility, if all cells require Clwd, is that different
splice forms are required for different stages of the cell cycle.
The presence of Clwd transcripts with different 5'UTR structures could also
influence its eventual expression levels by an alternate mechanism i.e. through the
upstream Open Reading Frame or uORF in the 5'UTR. In contrast to alternative
splicing, uORFs can control expression of the main ORF by repressing its
translation.
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By regulated alternative splicing and translation repression, Clwd's expression at
both the transcription and translation level may be tightly controlled. Given that I
have seen no difference in Clwd expression on a tissue level, this control could be at
a more cellular level.
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7.3 Clwd as a protein in silico and in vitro
What made Clwd interesting, in addition to a potential role in the wasted phenotype,
was its novelty. The 114 amino acid sequence that is predicted to form the Clwd
protein is unlike any known protein family. It contains no motifs that would allow a
function to be assigned to it and it has not been described previously in the literature.
It appears that despite our extensive knowledge of the mouse genome, there are
functional genes about which we know nothing. More precisely of the 29,201 genes
predicted to be encoded in the mouse genome, 9,785 are of unknown function.
Using motif recognition software the only functional motif Clwd appears to have,
other than a host ofpost-translational modifications, is a form ofGTP/ATP binding
site called a P loop. On the surface therefore it would seem, given that Clwd is a
small protein, perhaps it might be a good candidate for a new member of the small G
protein family as they are monomeric proteins with molecular masses of 20-40 kD.
However looking at the GTP-binding proteins more carefully it becomes clear that
the "P-loop" is one domain of the four required to bind and hydrolyse GTP. The
function of the P-loop fold in the protein is simply to position the triphosphate
moiety of a bound nucleotide65.
1 II III IV
[A/G]XXXXGK[S/T] DXXG NKXD EXSAX
Figure 7.2 Protein structure of small GTP-binding proteins. Motif I is the P loop - the only
motif possessed by Clwd.
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Clwd is therefore unlikely to be a small G protein i.e. belonging to the Ras
superfamily as it does not possess any of these other domains required to function as
a GTPase. However the fact that it does contain a sequence that could potentially
fold into a conformation that can interact with an ATP or GTP molecule could still
be important for an unrecognised function.
When the actual Clwd protein was examined by Western blot it was found that its
expression was as ubiquitous as the mRNA. The two main points worth noting were
that Clwd's apparent size on the blot was approximately 28kD and that in some
tissues there appeared to be a doublet. I believe both these features could be
explained if Clwd has post-translational modifications. Clwd does have the motifs
for a range ofmodifications such as O-GlcNAc and phosphate groups.
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7.4 Location and function of Clwd
7.4.1 Sub-cellular localisation of Clwd
Upon trying to elucidate the molecular function ofClwd, the first step to take was to
locate the protein within the cell. This was done by the co-localisation of various
organelle markers with Clwd and I found that the best co-localisation here was with a
protein Paxillin.
Paxillin is found at the site of focal adhesions connecting the extracellular matrix to
the actin cytoskeleton. Adhesion of cells to the extracellular matrix is fundamental
for normal cellular homeostasis. Signals are transduced through the integrin family
ofmatrix receptors. These, in turn, activate intracellular signalling cascades that
regulate the actin cytoskeleton network and the gene expression changes required for
embryogenesis, normal cell proliferation, survival and wound repair. The specialised
sites of cell contact formed between the plasma membrane and the extracellular
matrix, called focal adhesions comprise multiple structural and signalling proteins.
These proteins are associated with the cytoplasmic domains of integrins subunits
necessary for coordinating these signalling events66. Paxillin is a focal adhesion
• • ... • f\l
associated adaptor protein that recruits signalling molecules into a complex .
Although co-localisation experiments with Golgi markers did not give clear results
Clwd did have similar staining to Vtila/b in NIH/3T3 cells, Golgi proteins involved
in vesicle trafficking. Given these results it is worth noting that there is a family of
small G proteins that interact with Paxillin and yet are also found in the perinuclear
region of the Golgi. These are termed the ARF-GAPs. In fact focal adhesion
proteins like Paxillin and Vinculin have also been found to co-exist with various
ARF GAPs in both the perinuclear Golgi region and at the plasma membrane66. If
Clwd functions in one of the signalling pathways tied to Paxillin therefore, it would
not be unusual to see both perinuclear and more widespread cytoplasmic staining.
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7.4.2 Silencing of the Clwd gene in mammalian cells
As an initial experiment to assess Clwd's function in cells I decided to use RNAi to
silence the gene in a mouse fibroblast (NIH/3T3) cell line. This approach gave some
interesting results that suggested Clwd might be important in cell and/or nuclear
architecture or in normal cell growth and survival. However I found results using this
method to be inconsistent. Using chemically synthesised siRNA molecules and
transfecting them into cells to obtain a short-term silencing effect was the first
method described to reproduce RNAi in mammalian cell culture. However since this
was first discovered55, other methods of gene silencing by RNA interference have
been developed which may prove ofmore use in the future. In particular siRNA
expression vectors have been developed where a plasmid can be stably transfected
into cells and then be induced to produce hairpin siRNAs. This means the
transfection efficiency is no longer a problem as cells transfected can be selected for,
before induction of gene silencing. In addition, long term silencing can be achieved
rather than the 4-5 day silencing seen in using synthesised siRNAs.
As RNAi in cell lines is a relatively new methodology, new techniques and resources
are being developed all the time to make it more efficient. Therefore the
inconsistency seen here by using chemically synthesised siRNAs would not dissuade
me from using RNAi in the future to silence Clwd in cells but I would choose
another method
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7.5 Wasted immune system
The original reason for studying Clwd was in order to assess whether or not it was a
good candidate for playing a part in the phenotype of the mouse mutant wasted. As
discussed in the introduction to this thesis I believed that Clwd was the best
candidate to be the gene responsible for the immune system phenotype for a number
of reasons. Therefore a lot of effort was spent in characterising Clwd as it was a
novel gene, not described in the literature, and also unlike any other gene currently
known.
However upon a combined use of transgenic animals to rescue the wasted phenotype
and comparing Clwd expression in wild type and wasted mice, it became clear that
not only was Clwd not responsible for the wasted phenotype, but the loss ofEefla2
expression accounted for all pathologies associated with wasted mice.
As discussed in the introduction, one paper had described Eefla2 expression in
dendritic cells . I therefore chose to confirm this expression in bone marrow derived
dendritic cells by RT-PCR and found not only is Eefla2 expressed in dendritic cells,
but upon maturation of the dendritic cell there is a dramatic decrease in Eeflal
expression while Eefla2 expression increases, but only slightly. This implies that in
a wasted mouse the dendritic cells would have little or no eEFlA expression at all.
How this would affect the dendritic cell is uncertain.
As these dendritic cells express both eEFlA1 and eEFlA2 the fact that the loss of
eEFlA2 can have such a devastating effect implies that their individual functions in
dendritic cells are not equivalent. Alternatively it could be the reduction in the
amount of total eEFlA in wasted dendritic cells that causes the immune system
defects. However it is worth noting that while in the mouse eEFlA1 and eEFlA2 are
almost mutually exclusively expressed by cell type (except for some evidence of
eEFlA1 expression in the nuclei of spinal cord motor neurons), in most cultured cell
lines examined both are expressed. Therefore the presence of eEFlA1 in the
dendritic cells examined could be an artefact of cell culture and if one looked at
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dendritic cells in vivo only eEFlA2 would be expressed. If this were the case, then in
wasted dendritic cells there would be no eEFlA whatsoever and this could be
causing the effects seen in the wasted immune system.
How the loss of a translation elongation factor and/or a cytoskeleton interacting
protein in one component of the immune system can have such an affect on other
cells of the immune system - particularly in their ability to proceed through the cell
cycle with all the correct checkpoints is unclear. However what is clear is that the
loss of eEFlA2 does cause the immune system pathology. How this happens now
needs to be addressed.
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7.6 FutureWork
7.6.1 Clwd
Clwd is a novel, and at the moment, unique gene in both the human and mouse (and
other) genomes. As such, the amount ofwork to be done on it and its protein product
is almost endless at this stage. However some questions I would be very interested in
addressing are as follows.
It appears from my experiments that all of the alternatively spliced transcripts of
Clwd are expressed in every tissue examined. As I believe that the splice forms and
the uORF have some sort of regulatory function, albeit not a tissue-specific
regulation, I would like to examine the expression of these splice forms and the
protein at discrete points during the cell cycle. In mammalian cell culture there are
various drugs and methods of synchronising cells and stopping them in various
stages of the cell cycle. Examining Clwd expression in these stages may shed some
light on the reason for the different splice forms seen. I also believe it important to
confirm that the uORF is functional as a translation repressor, and if so, would the
different splice forms exert different levels of repression.
Given the unclear results following the Northern blot of the matched normal and
tumour tissue array I would like to carry out splice form-specific hybridisation
experiments using these sample to see if it is the increase or decrease in a particular
isoform that occurs during tumourigenesis
Turning to the protein product ofClwd, I would like to confirm that the sequence
predicted is indeed the true amino acid sequence of Clwd. I think the protein should
be purified and sequenced in addition to raising multiple antibodies against Clwd
using bacterially expressed protein and different peptide sequences for the creation of
anti-peptide antibodies. In addition any post-translational modifications need to be
mapped as these could also elucidate its function.
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In order to assess Clwd's function there are a variety of approaches to be taken. As
any interactions with known proteins are impossible to predict, given Clwd's lack of
homology to any known protein, an insight into its function could be gained from
using a yeast two hybrid screen to at least place Clwd within some system in the cell.
As Clwd is so widely and early expressed, I would anticipate that a straight-forward
knockout of Clwd may be embryonic-lethal and so I would instead create a
conditional knockout so that the loss of functional Clwd could be controlled
temporally and spatially to gain the maximum amount of information possible.
However I also anticipate, again given its expression pattern, that Clwd serves its
function at a cellular level. Therefore a long-term gene silencing experiment in
mammalian cell lines using RNAi expression vectors could reveal just as much, if
not more, information than a mouse knockout.
These are just the first round of experiments that I would carry out on Clwd next,
with their results informing and directing a more in depth study of Clwd and its
function.
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7.6.2 The immune system pathology of wasted mice
The discovery that the loss ofEefla2 expression is responsible for the immune
system phenotype is just the first step in elucidating this pathology. In order to
address eEFlA2's role here I would first check to see if it is expressed in any other
immune system cell types. Although no expression is seen in spleen and thymus as a
whole, I believe it would be important to ascertain that the effect of the loss of
eEFlA2 expression is mediated through the dendritic cells alone. Additionally it
would be important to look at Eeflal expression in native dendritic cells rather than
those derived from bone marrow and matured in culture to ensure its expression is
not an artefact of cell culture.
Because the neuromuscular deficiencies in wst/wst mice are so severe and kill the
mice by 28 days of age, if there was some way of separating out the two phenotypes
it may be possible to determine the progression of the immune system pathology. I
believe this could be done by the creation of bone marrow chimaeras where the bone
marrow of a wasted mouse could be transferred into a wild type mouse whose active
bone marrow had been removed by radiation. As the dendritic cells arise in the bone
marrow, the wild type mouse with wasted bone marrow would be expected to have
the immune deficiencies of the wasted mice but with a healthy neuromuscular system
allowing them to live longer so the wst/wst immune system could be studied in detail.
Alternatively, a conditional Eefla2 knockout could be created where Eefla2 is only
removed from the immune system. This would again be predicted to allow the mice
to live longer and so their immune system could be studied in isolation.
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7.7 Final Comments
This thesis, in addressing the question ofwhich gene is responsible for the immune
system defects in the mouse mutant wasted has generated questions as well as
answers. It has answered the original question - we now know the loss of eEFlA2 is
responsible for these defects. However it has introduced the novel gene, Clwd and
while headway has been made in characterising this gene and its protein product
many questions remain to be answered: What is the function of Clwd? What proteins
does it interact with? How is it regulated?
In addition, although we know the loss of eEFlA2 has a devastating effect on the
spleen and thymus ofwasted mice, we do not know how this effect is mediated.
I hope that these questions will be answered in the months and years to come and
that the answers will enlighten some of the fundamental mechanisms of cellular
function and immunological health.
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